Clarifying Values: An Updated and Expanded Systematic Review and Meta-Analysis

Holly O. Witteman^{1,2,3}, Ruth Ndjaboue^{1,2,} Gratianne Vaisson¹, Selma Chipenda Dansokho¹, Bob Arnold⁴, John F. P. Bridges⁵, Sandrine Comeau¹, Angela Fagerlin⁶, Teresa Gavaruzzi⁷, Melina Marcoux¹, Arwen Pieterse⁸, Michael Pignone⁹, Thierry Provencher¹, Charles Racine¹, Dean Regier¹⁰, Charlotte Rochefort-Brihay¹, Praveen Thokala¹¹, Marieke Weernink¹², Douglas B. White¹³, Celia E. Wills¹⁴, Jesse Jansen¹⁵

¹Department of Family and Emergency Medicine, Faculty of Medicine, Laval University, Quebec City, Canada ²VITAM Research Centre, Quebec City, Canada

³CHU de Québec Research Centre, Quebec City, Canada

⁴UPMC Palliative and Supportive Institute; University of Pittsburgh, Division of General Internal Medicine, Section of Palliative care and Medical ethics, Pittsburgh, PA, USA

⁵Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, OH, USA ⁶Department of Population Health Sciences, University of Utah School of Medicine, Salt Lake City, UT, USA ⁷Department of Developmental Psychology and Socialization, University of Padova, Padova, Italy ⁸Leiden University Medical Center, Leiden, The Netherlands

⁸Leiden University Medical Center, Leiden, The Netherlands

⁹Departments of Internal Medicine and Population Health, Dell Medical School, University of Texas, Austin, TX, USA

¹⁰School of Population and Public Health, Univ. of British Columbia, Vancouver, BC, Canada

¹¹School of Health and Related Research, University of Sheffield, Sheffield, UK

¹²Municipal Health Services (GGD), Enschede, The Netherlands.

¹³Program on Ethics and Decision Making in Critical Illness, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

¹⁴College of Nursing, Center on Healthy Aging, Self-Management and Complex Care, Ohio State University, Columbus, OH, USA

¹⁵Department of Family Medicine/CAPHRI, Maastricht University, Maastricht, The Netherlands

Corresponding author: Holly O. Witteman, 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry, Université Laval, Québec City, Québec, G1V 0A6, Canada, telephone: 418.656.2131 x3981, fax: 418-656.2465, email: holly.witteman@fmed.ulaval.ca

Abstract

Background: Patient decision aids should help people make evidence-informed decisions aligned with their values. There is limited guidance about how to achieve such alignment.

Purpose: To describe the range of values clarification methods available to patient decision aid developers, synthesize evidence regarding their relative merits, and foster collection of evidence by offering researchers a proposed set of outcomes to report when evaluating the effects of values clarification methods.

Data Sources: MEDLINE, EMBASE, PubMed, Web of Science, the Cochrane Library, CINAHL

Study Selection: We included articles that described randomized trials of one or more explicit values clarification methods. From 30,648 records screened, we identified 33 articles describing trials of 43 values clarification methods.

Data Extraction: Two independent reviewers extracted details about each values clarification method and its evaluation.

Data Synthesis: Compared to control conditions or to implicit values clarification methods, explicit values clarification methods decreased the frequency of values-disgruent choices (risk difference -0.04 95% CI [-0.06 to -0.02], p<.001) and decisional regret (standardized mean difference -0.20 95% CI [-0.29 to -0.11], p<0.001). Multicriteria decision analysis led to more values-congruent decisions than other values clarification methods (Chi-squared(2)=9.25, p=.01). There were no differences between different values clarification methods regarding decisional conflict (Chi-squared(2)=6.08, p=.05).

Limitations: Some meta-analyses had high heterogeneity. We grouped values clarification methods into broad categories.

Conclusions: Current evidence suggests patient decision aids should include an explicit values clarification method. Developers may wish to specifically consider multicriteria decision analysis. Future evaluations of values clarification methods should report their effects on decisional conflict, decisions made, values congruence, and decisional regret.

Introduction

Shared decision making aims to foster health-related decisions that are both informed by the best available evidence and aligned with what matters to the person or people affected by the decision. [1–4] Individual values are a critical ingredient in high quality individual health decision making. [5–7] What is important to one person might be different from what is important to others, and determining what is important to oneself can be difficult even if one has the appropriate information and evidence at hand. Therefore, patient decision aids should both present evidence appropriately and also support the process of clarifying and expressing patients' (and, when appropriate, other relevant stakeholders') values, with the goal of supporting alignment between values and decisions. Within patient decision aids, such support is offered by explicit values clarification methods.

Explicit values clarification methods require users to interact with something such as a worksheet or an interactive website to clarify what matters to them relevant to a health decision. Such methods have been shown to encourage desirable outcomes such as better alignment with patients' values [8, 9] and reduced decisional regret, the latter particularly among people with lower health literacy. [10] However, explicit values clarification methods are extremely diverse, [11], and there has been little guidance regarding their comparative effects on users' decision-making processes or outcomes [12], making it difficult for patient decision aid developers to know which explicit method to use. Patient decision aid developers might look towards the preference elicitation literature for guidance, but the guidance available [13] is often tailored towards aggregate level decision making, such as regulatory decisions [14] or health technology assessment [15], not for supporting individual-level decision making.

This updated review sought to build upon previous versions of the International Patient Decision Aids Standards' Chapter on Values Clarification [16, 17] as well as previous evidence syntheses that have established the advantages of explicit values clarification methods over implicit methods or no values clarification. [8, 9] We sought to advance the science and practice of values clarification methods in three ways. First, we aimed to offer clear definitions and an annotated summary of existing approaches that have been or could be used as values clarification methods. Second, we aimed to synthesize evidence of different techniques' effects on health decision outcomes. Third, we aimed to foster future evidence by offering researchers a proposed set of outcomes to consider when evaluating the effects of values clarification methods.

Definitions

Part of the challenge in studying or using values clarification methods is that definitions vary and terms like 'values' are used imprecisely in the patient decision support literature. [18, 19] Another challenge is that there is substantial overlap between values clarification methods used in patient decision support and preference elicitation methods used in health economics. To bring clarity to this imprecision and overlap, we adopt working definitions in Table 1 for use in this paper.

Term	Definition adopted in this paper
Values	An umbrella term referring to what matters to an individual relevant to a health decision. Values may be directly relevant to decisions (e.g., "beliefs, feelings, or perceptions regarding attributes of a treatment option") or indirectly relevant (e.g., goals; worldviews; family, religious, or cultural values). [20] Values may be represented qualitatively or, in some cases, quantitatively. This definition is

Table 1. Definitions of Terms

	deliberately broad.
Values clarification	"The process of sorting out what matters to an individual relevant to a given health decision." [11] This definition emphasizes that what matters to an individual may be broader than attribute-specific values. What matters may also include preferences, concerns, and issues to do with the context of a person's life within which they would need to implement a decision.
Values clarification methods	"Strategies that are intended to help patients evaluate the desirability of options or attributes of options within a specific decision context, in order to identify which option [they] prefer." [17]
Implicit values clarification methods	Strategies for facilitating values clarification that do not require people to interact with anything or anyone; e.g., describing "options in enough detail that clients can imagine what it is like to experience the physical, emotional, and social effects," [9] or simply encouraging people to think about what matters to them.
Explicit values clarification methods	Strategies for facilitating values clarification that require people to interact with something or someone; e.g., filling out a worksheet, using an interactive website, having a semi-structured conversation with another person with the explicit purpose of clarifying values, or engaging in another structured exercise.
Preferences	The extent to which a decision option or health state is desirable or acceptable, either in the abstract or in comparison to other options or health states. Preferences may be represented qualitatively or, more commonly, quantitatively. [21]
Preference elicitation methods	Processes by which preferences are drawn out. [11] Preference elicitation methods may vary according to the theory informing them. They are highly related to values clarification methods. Although older terms "revealed" and "stated" preference elicitation methods are no longer recommended, readers who encounter these terms in previous preference elicitation literature should note that these may overlap with implicit and explicit values clarification methods, respectively.

As noted above, we continue to use the term values clarification even though this is sometimes misinterpreted as implying a narrow definition of values. Changing terms makes it difficult for people who are new to a field to connect the dots across decades of previous research. It is clear that previous research in values clarification addressed issues that were broader than valuation of treatment-specific attributes. [16] In this update, we therefore move forward with the older terms, now with more clarity about what they mean in our presentation of the evidence.

Theoretical Rationale

Our interdisciplinary team determined that the theoretical rationale for values clarification required only a small edit, shown in square brackets, to reflect the focus on explicit methods. Like Fagerlin and colleagues, we assert the theoretical rationale for explicit values clarification methods as being that they, "should aim to [explicitly] facilitate at least one or more of the following six decision-making processes: 1) Identifying options, which can include either the narrowing down of options, or the generation of options that were not offered at the outset, 2) Identifying attributes of the situation and/or the options which ultimately affect the patient's preference in a specific decision context, 3) Reasoning about options or attributes of options, 4) Integrating attributes of options using either compensatory or both compensatory and non-compensatory decision rules, 5) Making holistic comparisons, and 6) Helping decision makers retrieve relevant values from long-term memory." [17] Pieterse and colleagues provided theory-based recommendations on processes that values clarification methods could aim to facilitate. [22]

Although reasoning is one of the potential processes supported by values clarification, neither the definition nor the theoretical rationale of values clarification methods requires that people who are being supported in making a personal health decision must rationally deliberate about each option, nor that the goal must always be a fully rational choice. In some decision-making situations, rational deliberation and rational choice may be desired, while in others, they may not. [23, 24]

Explicit Values Clarification Methods

Table 2 organizes strategies that can be used as explicit values clarification methods in patient decision aids, building upon previously-developed lists of types of values clarification methods [7, 11] and reviews of preference elicitation methods. [25, 26] Methods range from highly structured strategies that can also be used for preference elicitation in the context of health policy decision making to substantially less structured strategies. While not every use of a given method will be exactly the same, we deemed them functionally similar in terms of how they might be used and what the user experience might be in a patient decision aid. Patient decision aids may use multiple strategies. For example, a user may be asked to use a rating scale or visual analog scale whose values are then used in a decision analytic model.

Method	Description
Adaptive Conjoint Analysis (example [27])	The user rates a series of sets of attributes and their levels, where choices presented are tailored to earlier answers.
Allocation of Points (example [28])	The user has a "budget" to "spend" on decision attributes, according to their importance.
Analytical Hierarchy Process (example [29])	The user is asked to compare sets of options relative to predefined decision criteria.
Best-Worst Scaling (example [30])	The user is asked to indicate the best and the worst in sets of options with different attributes and levels.
Decision Analysis or Multicriteria Decision Analysis (umbrella term*) (resource [31, 32])	The user is asked to directly indicate the extent to which a decision attribute or outcome matters to them or how good or bad they deem it to be. These values are then used in a model that calculates alignment between what matters to the user and the available decision options.
Discrete Choice Experiments (example [33])	The user is asked to make a series of choices between two (or more) alternatives, where each alternative is characterized by attributes and their associated levels.
Open Discussion (example [34])	The user makes a list and/or discusses what matters to them in an unstructured or semi-structured discussion.
Pros and Cons (resource [35])	The user lists advantages (pros) and disadvantages (cons) of options and/or indicates the relevance ('this matters to me') or importance (e.g., on a Likert scale) of each advantage or disadvantage
Ranking (example [36])	The user is asked to place attributes in order of importance, relative to each other.
Rating Scales (example [37])	The user indicates the importance of an attribute on a visual analog scale (e.g., paper-based visual analog scale, online slider) or Likert scale approximating a visual analog scale. If the rating is then used to calculate and show which option fits best, the method is classified as (multicriteria) decision analysis.

Table 2. Values Clarification Methods

Social Matching (example [38])	The user "observes different characters' decisions and/or decision-making processes and identifies 1 or more characters" with whom they identify. [11]
Standard Gamble (example [39])	The user indicates their willingness to accept a certain risk of death in order to avoid a particular health state by choosing between the certainty of living in that health state for the remainder of their life versus a gamble between two possible outcomes: life in a state of optimal health, with probability p, or immediate death, with probability $(1-p)$.
Time Tradeoff (example [39])	The user indicates how many years in their current health state they would be willing to 'trade off', in order to regain full health.

*Multicriteria decision analysis or decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete choice experiments, best-worst scaling.) When applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term "multicriteria decision analysis," or, for brevity in figures, "decision analysis." Additionally, although within multicriteria decision analysis, the user may be asked to rate attributes on rating scales, what distinguishes multicriteria decision analysis from other methods such as rating scales is that the model calculates how well or poorly the options align with what matters to a user.

Methods

Our overall methods were guided by the Cochrane Handbook. We report according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [40] guidelines.

Eligibility criteria

We included published reports of comparative evaluations of explicit values clarification methods, whether they were called 'values clarification methods' in the publications or not. This meant that we included trials of preference elicitation methods that had been trialed as values clarification methods; for example, multi-criteria decision analysis or discrete choice experiments. We included evaluations using comparative methods; i.e., randomized controlled trials or randomized experiments of one or more values clarification methods. The comparisons could be one or more values clarification methods compared to a control method, or compared to each other. Because we sought to understand the effects of values clarification methods, we excluded evaluations using descriptive study designs (e.g., acceptability and feasibility study, development study), observational study designs (e.g., reporting outcomes before and after use of a values clarification method), and reports of values clarification methods that did not evaluate the method independently of the patient decision aid in which it was used. Randomized experiments comparing one or more values clarification methods had to use distinctly different methods, meaning that more than the content or presentation of information in the values clarification method varied.

We did not apply language restrictions. We applied date restrictions to the portion of the review for which we had already conducted a systematic review (i.e., evaluations of values clarification methods that used the term 'values clarification'. [12, 17] Specifically, for this subgroup, we added articles indexed or published starting in 2014 to the existing set of articles indexed or published prior to 2014 that we had already identified using the same search strategy. We applied no date restrictions to the new, expanded portion of the review (i.e., evaluations of values clarification').

Information sources

We performed a systematic literature search in MEDLINE, EMBASE, Web of Science, the Cochrane Library, and CINAHL.

Search strategy

We developed a draft search strategy in collaboration with an information specialist (FB, see Acknowledgments). Search strategies for each database are shown in Online Appendix 1. We reviewed search strategies with all authors to ensure they were inclusive of relevant preference elicitation methods that might be used for values clarification. We conducted hand searches by reviewing articles that cited the previous version of these standards (values clarification chapter) or a previous systematic review of values clarification methods.

Study records: Data management

We managed data with Covidence (covidence.org, Melbourne, Australia), reviewing data records at regular team meetings.

Study records: Selection process

Two independent reviewers (SC, MM, TP, CR, CRB) screened titles and abstracts to assess potential relevance, with a third reviewer adjudicating discrepancies and discussions of questions and points of disagreement at regular team meetings. Two independent reviewers then reviewed the full text of all articles deemed potentially relevant based on their title and abstract. Discrepancies in inclusion and exclusion at full text were adjudicated through team discussions at regular meetings until we reached consensus.

Study records: Data collection process

Two independent, trained research team members (SC, MM, TP, CR, CRB) extracted data from each article using a standardized and pilot-tested data extraction form based on a previous form [12] and adapted to this review. We resolved lack of agreement through discussion until consensus was reached. We contacted authors to collect any needed data that they did not report or were unable to report in their publication.

Data items

Regarding study participants, we recorded the sample size for control and intervention groups along with basic inclusion and exclusion criteria and whether or not they were making the actual decision or if the study was hypothetical. We defined a hypothetical scenario as one in which people are asked (explicitly or implicitly) to imagine that they are in a certain situation or facing a certain decision. We defined a real scenario as one in which people are facing a decision (e.g., because they have received a diagnosis) or are members of a population likely to face the decision in the near term (e.g., parents of children eligible to receive vaccines within the coming months.)

Regarding interventions, we recorded the type of explicit values clarification method as listed in Table 2. We also recorded specific characteristics of each values clarification method, namely, whether it explicitly requires the user to engage with tradeoffs (i.e., considering which potential harms are acceptable in exchange for their associated potential benefits), whether it explicitly shows the user the correspondence between their options and what they value, and which, if any, theoretical or conceptual framework underpins it. Where relevant, we recorded whether a variable was collected via self-report, meaning whether responses were completed by participants themselves, or by independent researchers based on direct observation, including coded qualitative data.

For comparators (controls) we recorded whether the comparator was no values clarification method or an implicit method, and treated both as equivalent controls. The Cochrane review of patient decision aids

specifies that all patient decision aids must contain implicit values clarification methods at minimum [9] and it is accordingly rare to have patient decision aids that do not present potential benefits and harms of options in organized ways. In other words, in the context of patient decision aids, there is no meaningful distinction between implicit methods and no values clarification. The different terminology is simply a function of how authors choose to name their control. We also recorded studies that compared different types of explicit values clarification methods to each other.

Outcomes

Whenever such data were available, we extracted data regarding values congruence as our primary outcome, as well as secondary outcomes: decision readiness (worry, decision uncertainty, decision-making preparation, knowledge); decisional conflict; decision made; post-decision and post implementation health and well-being (decisional regret, longer-term health outcomes). Following data extraction by pairs of trained reviewers (SC, MM, TP, CR, CRB), three authors (HOW, SCD, JJ) mapped all outcomes into broad outcome groups: worry (including perceived risk), decision uncertainty (not including decisional conflict), decisional conflict (decisional conflict scale or any subscales), decision-making preparation (including self-efficacy for decision-making), beliefs (including beliefs about the condition or underlying decision structure), knowledge, values (including reported utilities), shared decision making, effects on communication (including quality, length, or existence of communication), satisfaction with care, preferences, decision (choice made and implemented) or decisional intent (choice intended, or made and not yet implemented), values congruence, informed decision making, post-decision feelings (including satisfaction, regret), post-decision health, and user assessment of the intervention (including acceptability, satisfaction, perceived balance.) We conducted meta-analyses on primary outcome values congruence and secondary outcome decisional conflict, as these outcomes had sufficient studies to do so.

Risk of bias in individual studies

Independent, trained research team members assessed risk of bias for each study using methods as defined in the Cochrane Handbook, section 8.5. [41] We conducted quantitative data syntheses with and without studies identified as being at high risk of bias to determine the sensitivity of overall findings to these studies.

Data synthesis

We synthesized frequency-based results (e.g., how many values clarification methods reflect a given design) descriptively. To synthesize effects on outcomes, we pooled all experiments that evaluated a values clarification method against no values clarification method or an implicit method. For multi-armed studies in which the comparison of a decision aid with and without a values clarification method included an arm that was not relevant to our comparison of interest (for example, an information booklet serving as a control condition in an evaluation of the decision aid) we ignored the third arm. For multi-armed studies containing two or more different values clarification method against implicit values clarification or control, we considered each comparison of a values clarification method against implicit values clarification, meaning that each of the multi-armed studies included in this review contributed multiple comparisons to the pooled set.

To meta-analyze results for values congruence, we pooled results using risk differences and applying a random effects model. We extracted dichotomous data indicating the frequency (i.e., number of events and sample size) of values discongruent decisions. To meta-analyze results for decisional conflict, we pooled results using standardized mean differences applying a random effects model. We extracted data on total scores on the Decisional Conflict Scale. We explored and reported consistency using Higgins I^2 [42]. We used the Cochrane Risk of Bias tool to assess study bias along 7 domains as well as to assess an overall risk

of bias. Where data permitted, we conducted subgroup meta-analyses of different types of explicit values clarification methods and of explicit values clarification methods that do and do not contain specific design features already identified in previous work [11], namely, whether the method explicitly requires the user to engage with tradeoffs, whether it explicitly provides the user with the implications of what they value, and which, if any, theoretical or conceptual framework underpins it. We used p=0.05 as a threshold for statistical significance and conducted analyses in RevMan, version 5.4.

Results

Articles identified

Out of 30,648 records screened at the title and abstract stage and 279 screened at the full text stage, we identified 33 articles that met our inclusion criteria describing trials of 43 values clarification methods. Twenty-four of the articles were new articles identified in this update of IPDAS. We excluded 2 of the articles previously included in the IPDAS Values Clarification Chapter because they did not meet our revised inclusion criteria requiring randomized controlled trials and instead reported, for example, pre-post study designs. The PRISMA diagram of included articles is shown in Figure 1.

Figure 1. PRISMA Diagram



The decision context varied across studies. Out of the 43 included trials, 25 (58%) addressed treatment decisions, 9 (21%) screening decisions, 4 (9%) prevention, 3 (7%) genetic testing, and 2 (5%) diagnostic testing. Thirteen of the 43 trials (30%) centered around a yes/no decision to take an option or not, 18 (42%) a choice between two or more options and 12 (28%) both a yes/no and a choice between two or more options. Most decisions (22/43, 51%) were real decisions, meaning that the person was making this decision in their actual life. The rest were hypothetical (18/43, 42%) or it was not entirely clear whether the decision was real or hypothetical (3/43, 3%). The most commonly-reported outcomes were decisional conflict and/or its subscales (29/43, 67%), decision and/or decisional intentions (22/43, 51%), knowledge (13/43, 30%), and values congruence (12/43, 28%).

As shown in the overview of included studies in Table 3, there was substantial diversity in the types of values clarification methods used. Decision analysis or multicriteria decision analysis was the most commonly trialed method. Full study details are available in Online Appendix 2.

Type(s) of Values Clarification Method(s)	Study	Population*	Decision	Summary of findings			
Adaptive Conjoint Analysis	de Achaval and others 2012 [43]	n=208 people with knee osteoarthritis	Whether to receive medication and therapy or total knee arthroplasty	Values clarification method decreased decisional conflict and required more intense cognitive involvement. Values clarification method increased self- confidence in and preparation for shared decision-making, and increased arthritis self-efficacy.			
Adaptive Conjoint Analysis	Fraenkel and others 2007 [44]	n=87, age at least 60 years old, self report of pain involving one or both knees on most days of the month	Choice between five treatments for knee pain				
Adaptive Conjoint Analysis	Hess and others 2015 [45]	n=374 women aged 18 years or older with abnormal uterine bleeding & potential candidates for either surgical or medical treatment	Whether or not to be treated for abnormal uterine bleeding, and, if yes, which treatment to undertake	Values clarification method did not reduce decision regret nor improve treatment satisfaction.			
Adaptive Conjoint Analysis	Hutyra and others 2019 [46]	n=200 people between 18 and 35 years of age at risk for experiencing a first-time anterior shoulder dislocation	Operative or nonoperative treatment for first-time anterior shoulder dislocation	Values clarification method increased alignment between patients' treatment decisions and evidence-based recommendations.			
Adaptive Conjoint Analysis	Jayadevappa and others 2015 [47]	n=743 people with newly diagnosed localized prostate cancer	Choice between six options for early stage prostate cancer	Values clarification method improved satisfaction with care, satisfaction with decision, reduced regrets, and aligned treatment choice with risk category.			
Allocation of Points	Witteman and others 2020 [48]	n=817 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 6b in paper) increased values congruence and reduced decisional conflict.			
Analytical Hierarchy Process	Myers and others 2003 [49]	n=199 men aged 50 to 69 with no personal history of prostate cancer/benign	Whether or not to be screened for prostate cancer	Values clarification method decreased rates of prostate cancer screening. Race/ethnicity analyses showed African American men increased screening while white men decreased screening			

Table 3. Study Details

Applytical	Muoro and	n 242 African	Whathar ar pat to be	Values elerification method increased		
Analytical	iviyers and	n=242 Amcan-	whether of hot to be	prostate cancer screening		
		American men, 40-69	screened for prostate	prostate cancer screening.		
Process	[ວບ]	vears of age and no cancer, and if yes,				
		history of prostate				
		cancer	method/extent of			
			screening			
Best-Worst	Shirk and	n=122 men with	Choice between three	Values clarification method decreased		
Scaling	others 2017	incident localized	options for incident	decisional conflict.		
	[51]	prostate cancer	localized prostate			
			cancer			
Decision	Bekker and	n=106 pregnant	Whether or not to have	Values clarification method helped women		
Analysis**	others 2004	women receiving a	a prenatal diagnosis	make more informed prenatal diagnosis		
	[52]	screen positive	for Down syndrome	decisions.		
		maternal serum				
		screening result				
Decision	Clancy and	n=1280 resident and	Choice between three	Values clarification method resulted in		
Analysis**	others 1988	faculty physicians	options to manage risk	greater action-taking (screening or		
-	[53]	unvaccinated against	of hepatitis B	vaccination.)		
		Hepatitis B	-			
Decision	Feldman-	n=156 people with	Choice between more	Values clarification method increased		
Analysis**	Stewart and	newly diagnosed	than five main options	preparation for decision making and		
-	others 2012	prostate cancer	for early stage prostate	decreased decision regret. Decision conflict		
	[54]		cancer	decreased with and without values		
				clarification method.		
Decision	Hopkin and	n=349 adults asked to	Choice between five	Values clarification method reduced		
Analysis**	others 2019	imagine that they had	commonly-used statins	decisional conflict and increased levels of		
	[55]	to choose a statin	,	preparation for decision making.		
D						
Decision	Montgomery	n=217 adults aged	Whether or not to start	Values clarification method increased		
Analysis**	and others	30-80 years with	drug therapy for	knowledge and reduced total decisional		
	2003 [56]	newly diagnosed	hypertension	conflict by significantly reducing scores on		
		hypertension		uninformed, unclear values and		
				unsupported subscales and somewhat		
				reducing scores on uncertainty subscale.		
				Values clarification method did not		
				influence scores on decision quality		
				subscale, nor did it change state anxiety,		
				decision intention, nor ultimate decision.		
Decision	Montgomery	n=742 pregnant	Choice of planned	Values clarification method reduced		
Analysis**	and others	women with one	mode of delivery	decisional conflict and increased frequency		
	2007 [57]	previous lower		of having a vaginal birth.		
		segment caesarean				
		section				
Decision	Witteman and	n=407 parents who	Whether their child	Values clarification method had no effect		
Analysis**	others 2015	make medical	would receive a	on values congruence. Values clarification		
	[58]	decisions for at least	vaccine against	method combined with best practices in risk		
		one child aged 6	influenza this flu	communication increased intentions to		
		months to 18 years	season	vaccinate, particularly among participants		
		and whose child had		who had not had their children vaccinated		
		not yet received the		against influenza in the past 5 years.		
		flu vaccine				
Decision	Witteman and	n=1731 adults asked	Choice between two	Values clarification method (strategies 2a.		
Analysis**	others	to imagine they had	hypothetical surgeries	2a+2b, 6c, 6b+6c in paper) increased		
-	2020*** [48]	been diagnosed with	for colon cancer	values congruence and reduced decisional		
		colon cancer deciding		conflict this was when measured (strategies		
		between two		6c, 6b + 6c in paper).		
		treatment options				
Discrete	Brenner and	n=615 people	Whether or not to be	Values clarification method influenced		
Choice	others 2014	between the ages of	screened for colorectal	choice of most important screening test		
Experiment	[59]	50 and 75 at average	cancer, and, if yes,	attribute but did not affect unlabeled test		

		risk for colorectal cancer	which screening test to use	preference, values clarity, nor intent to be screened.
Discrete Choice Experiment	Pignone and others 2012 [60]	n=104 adults 48-75 at average risk for colon cancer	Whether or not to be screened for colorectal cancer, and, if yes, which screening test to use	Values clarification method influenced choice of most important attribute, but did not affect values clarity, intent to be screened, or choice of unlabeled screening test.
Discrete Choice Experiment	Pignone and others 2013 [61]	n=604 men aged 50- 70 at average risk of prostate cancer	Whether or not to be screened for prostate cancer	Values clarification method slightly reduced choice of dying as the most important attribute and increased unlabeled PSA-like screening option but did not influence intent to be screened.
Open Discussion	Au and others 2012 [62]	n=306 people with chronic obstructive pulmonary disease	Preferences for end-of- life care	Values clarification method helped identify what mattered to patients regarding end-of- life care and communication. Quality of communication improved.
Open Discussion	Epstein and others 2018 [63]	n=99 people with advanced gastrointestinal cancer	Choice between options for end-of-life care	Values clarification method improved communication about future medical cancer care but had no effect on decisional conflict or well-being and increased distress.
Open Discussion	Kennedy and others 2002 [64]	n=894 women with uncomplicated menorrhagia	Choice between treatment options for menorrhagia	Values clarification method resulted in minimal improvements in self-reported health status, lower use of a more invasive treatment, higher patient satisfaction, more frequent clinician perceptions of "longer than usual" consultations, and lower overall costs. Providing information alone did not affect treatment choices.
Open Discussion	Lerman and others 1997 [65]	n=700, Women aged 18-75 years who had had at least one first- degree relative with breast and/or ovarian cancer	Whether or not to provide a blood sample for BRCA1 testing in the future	Values clarification method increased the perceived importance of the limitations and risk of BRCA1 testing and decreased the perceived importance of the benefits of BRCA1 testing. No effect of values clarification method on intent to treat.
Open Discussion	Matheis-Kraft and others 1997 [66]	n=60 women over age 70 with at least one family member or friend who might act as their proxy to make decisions about life- sustaining treatment	Preferences for care in case of decisional incapacity	Values clarification method's effectiveness or lack thereof depended on which statistic (kappa or percent agreement) was used to measure concordance between women and proxies.
Pros and Cons	Abhyankar and others 2010 [67]	n=30 healthy women asked to imagine having been diagnosed with breast cancer, undergone lumpectomy and suggested chemotherapy by th <u>eir doctor</u>	Choice between having standard adjuvant chemotherapy or taking part in a clinical trial testing a new chemotherapy for early stage breast cancer	Values clarification method resulted in more use of personal values when evaluating attributes of options, somewhat less ambivalence, less uncertainty and did not change preferred option.
Pros and Cons	O'Connor and others 1999 [68]	n=201 women aged 50-69 who had never used hormone therapy	Whether or not to take hormone replacement therapy after menopause	Values clarification method had no effect on clarity of values, values congruence, total decisional conflict, other subscales of Decisional Conflict Scale, nor acceptability of intervention.
Pros and Cons	Paquin and others 2018 [69]	n=1000 people aged 18-44 who were pregnant or whose	Whether or not to use genomic sequencing to identify genetic	Values clarification method decreased parental beliefs against genomic sequencing.

		partner was pregnant or planning to become pregnant in the next 2 years	variants in one's child				
Pros and Cons	Peinado and others 2020 [10]	n=1000 people aged 18-44 who were pregnant or whose partner was pregnant or planning to become pregnant in the next 2 years	Whether or not to enroll their newborn child in a medical research study that would involve screening for genetic conditions	Values clarification method decreased decisional regret and increased clarity of personal values but had no effect on overall decisional conflict nor on intent to have one's child tested.			
Pros and Cons	Witteman and others 2020 [48]	n=772 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 4b in paper) reduced decisional conflict but did not change values congruence.			
Rating Scales	Garvelink and others 2014*** [70]	n=271 healthy women	Whether or not to undergo fertility preserving procedures prior to cancer treatment	Values clarification method had no effect on knowledge nor decisional conflict.			
Rating Scales	Kuppermann and others 2014 [71]	n=710 pregnant women who had not yet undergone screening or diagnostic testing for fetal aneuploidy in the current pregnancy	Whether or not to have any screening or diagnostic testing for fetal aneuploidy; if screening or testing is desired, whether to start with screening or with invasive diagnostic testing; and which specific screening and/or diagnostic test(s) to undergo.	Values clarification method increased patient knowledge and resulted in less invasive prenatal test use and more informed choices. Values clarification method did not change decisional conflict nor decisional regret.			
Rating Scales (with and without decision analytic summary)	Feldman- Stewart and others 2006 [72]	n=90 male volunteers asked to imagine that they had just been diagnosed with early- stage prostate cancer	Choice between four options for early stage prostate cancer	Participants preferred values clarification method with decision analytic summary over values clarification method without summary and no values clarification method.			
Rating Scales	Witteman and others 2020 [48]	n=785 adults asked to imagine they had been diagnosed with colon cancer	Choice between two hypothetical surgeries for colon cancer	Values clarification method (strategy 6a in paper) reduced decisional conflict but did not change values congruence.			
Rating Scales + Ranking	Brenner and others 2014 [59]	n=614 people between the ages of 50 and 75 at average risk for colorectal cancer	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use	Values clarification method increased the importance placed on risk reduction as an important attribute but did not affect unlabeled test preference, values clarity, nor intent to be screened.			
Rating Scales + Ranking	Pignone and others 2012 [60]	n=104 adults 48-75 at average risk for colon cancer	Whether or not to be screened for colorectal cancer, and, if yes, what screening test to use	Values clarification method influenced choice of most important attribute, but did not affect values clarity, intent to be screened, or choice of screening test.			
Rating Scales + Ranking	Pignone and others 2013 [61]	n=609 men aged 50- 70 at average risk of prostate cancer	Whether or not to be screened for prostate cancer	Values clarification method increased the importance placed on dying but did not influence intent to be screened.			
Rating Scales + Ranking	Sheridan and others 2010 [73]	n=137 men aged 45- 80 with no prior history of cardiovascular	Whether or not to initiate behaviours to prevent coronary heart disease, and, if so,	Values clarification method had no effect. Decisional conflict, perceived values congruence, and self-efficacy for health behaviours improved with and without			

		disease	which behaviours	values clarification. Behavioural intentions did not change.
Time Tradeoff +	Frosch and others 2008	n=611 men older than 50 years	Whether or not to be screened for prostate	Values clarification method increased cancer knowledge scores and decreased
Rating Scales	[74]		cancer	decisional conflict.

*n is given for the study as a whole. See supplementary appendix for further details about each study.

**Decision analysis or multicriteria decision analysis is an umbrella term. It encompasses some of the other, more specific categories (e.g., discrete choice experiments, best-worst scaling.) Throughout the paper, when applicable, we use the more specific, narrower categories. Otherwise, we use the umbrella term "multicriteria decision analysis," or, for brevity in figures, "decision analysis."

***Garvelink and colleagues 2014 and Witteman and colleagues 2020 each reported multiple experiments testing values clarification methods that did not differ in type nor in outcomes. Pooled results are therefore presented here.

Quality assessment

Overall study quality was acceptable, with the majority of studies at low risk of bias on most elements. Eight studies were deemed to be at high risk of bias on one element; the majority in Blinding of Participants and Personnel (Performance Bias). Eighteen additional studies were deemed unclear on this element. Blinding of Outcome Assessment (Detection Bias) was the next most common source of potential bias, with 1 study at high risk of bias and 20 more unclear. Full details of risk of bias assessments are available in Online Appendix 3.

Values Congruence

As shown in Figure 2a, included explicit values clarification methods, as a group, increased values congruence. Eleven out of 43 trials (26%) reported the number of people who made values-congruent or values-disgruent decisions. The pooled risk difference of making a values-disgruent decision when using one of the trialed values clarification methods was -0.04 95% CI [-0.06 to -0.02], p<.001. The I² of 28% indicates a relatively low level of statistical heterogeneity.

Figure 2b shows a statistically significant subgroup difference by type of values clarification method. The results suggest that decision analysis is more likely to encourage values-congruent decisions compared to other explicit values clarification methods within this set of trials (Chi-squared(2)=9.25, p=.01). The results show no significant subgroup differences by trade-offs, implementation, theory or by implication of the decision. (See Online Appendix 3.) There were no studies in this analysis with a high risk of bias.

Figure 2a. Values Congruence*: Overall (All Values Clarification Methods Together)

	VCN	1	no VC	M	Risk Difference			Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	
Sheridan 2010	3	62	6	75	5.9%	-0.03 [-0.11, 0.05]	2010	
Jayadevappa 2015	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	-
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	
Witteman 2020 4b	74	350	93	422	9.9%	-0.01 [-0.07, 0.05]	2020	
Witteman 2020 6a	85	363	93	422	9.8%	0.01 [-0.05, 0.07]	2020	
Witteman 2020 6b	68	395	93	422	10.9%	-0.05 [-0.10, 0.01]	2020	
Witteman 2020 6b + 6c	59	413	93	422	11.6%	-0.08 [-0.13, -0.03]	2020	
Witteman 2020 6c	79	440	93	422	11.2%	-0.04 [-0.09, 0.01]	2020	
Witteman 2020 2a	43	239	59	217	6.5%	-0.09 [-0.17, -0.02]	2020	-
Witteman 2020 2a + 2b	26	237	41	217	8.4%	-0.08 [-0.14, -0.01]	2020	
Total (95% Cl)		3148		3271	100.0%	-0.04 [-0.06, -0.02]		•
Total events	584		735					
Heterogeneity: Tau ^z = 0.00; Chi ^z = 13.88, df = 10 (P = 0.18); i ^z = 28% Test for overall effect: Z = 3.42 (P = 0.0006)						6		-0.5 -0.25 0 0.25 0.5 Eavours VCM Eavours po VCM
	-							

*Events refer to values-disgruent decisions. The meta-analysis synthesizes the risk across trials of making a valuesdisgruent decision.

Figure 2b. Values Congruence* by Type of Values Clarification Method

.....

	VCN	1	no VCM			Risk Difference	Risk Difference	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.2.1 Decision analysis								
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	
Witteman 2020 6b + 6c	59	413	93	422	11.6%	-0.08 [-0.13, -0.03]	2020	
Witteman 2020 6c	79	440	93	422	11.2%	-0.04 [-0.09, 0.01]	2020	-
Witteman 2020 2a	43	239	59	217	6.5%	-0.09 [-0.17, -0.02]	2020	
Witteman 2020 2a + 2b	26	237	41	217	8.4%	-0.08 [-0.14, -0.01]	2020	
Subtotal (95% CI)		1534		1480	42.1%	-0.07 [-0.10, -0.04]		•
Total events	302		396					
Heterogeneity: Tau ² = 0.00); Chi <mark>²</mark> = 1	1.67, df	= 4 (P =	0.80); P	²=0%			
Test for overall effect: Z = 4	4.79 (P ≺	0.0000	11)					
2.2.2 Pros and cons								
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	
Witteman 2020 4b	74	350	93	422	9.9%	-0.01 [-0.07, 0.05]	2020	<u>+</u>
Subtotal (95% CI)		451		522	12.5%	-0.00 [-0.06, 0.05]		•
Total events	109		126					
Heterogeneity: Tau ² = 0.00); Chi ² = (0.12, df	'= 1 (P =	0.73); P	²=0%			
Test for overall effect: Z = 0	0.17 (P =	0.86)						
2.2.3 Other								
Sheridan 2010	3	62	6	75	5.9%	-0.03 [-0.11, 0.05]	2010	
Jayadevappa 2015	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	1
Witteman 2020 6a	85	363	93	422	9.8%	0.01 [-0.05, 0.07]	2020	+
Witteman 2020 6b	68	395	93	422	10.9%	-0.05 [-0.10, 0.01]	2020	
Subtotal (95% CI)		1163		1269	45.4%	-0.02 [-0.04, 0.01]		•
Total events	173		213					
Heterogeneity: Tau ² = 0.00); Chi ² = 3	2.58, df	'= 3 (P =	0.46); P	²=0%			
Test for overall effect: Z = 1	1.27 (P =	0.21)						
Total (95% CI)		3148		3271	100.0%	-0.04[-0.06, -0.02]		•
Total events	594	5140	726	3271		2004 [-0100] -0102]		
Hotorogonoity: Tou ² - 0.00	004).⊂hi≩= 1	1200 /	733 4f = 1070	- 0.10	\· ≅ – 2004			
Telefoyenelly, rau ⁻ = 0.00		13.00, l 0.0000	ar – 10 (F ⊳	- 0.18	7,1 - 20%	D		-1 -0.5 Ó 0.5 1 [°]
Test for overall ellect: $Z = $.	5.42 (F =	0.0000	7) 1. df = 1. /5	0.04	0) 12 - 70	1.402		Favours VCM Favours no VCM
Test for subgroup differences: Unit = 9.25, df = 2 (P = 0.010), if = 78.4%								

*Events refer to values-disgruent decisions. The meta-analysis synthesizes the risk across trials of making a valuesdisgruent decision.

Decisional Conflict

As shown in Figure 3a, explicit values clarification methods decrease decisional conflict. For the 14/43 (33%) trials for which we had complete data, the pooled standardized mean difference for decisional conflict was - 0.20 95% CI [-0.29 to -0.11], p<0.001. The I² of 67% represents moderate to high statistical heterogeneity. Figure 3b shows there was no significant subgroup difference by type of values clarification method (Chi-squared(2)=6.08, p=.05). We found no significant subgroup differences by trade-offs, implementation, theory, implication, nor risk of bias (see Online Appendix 3).

Figure 3a. Decisional Conflict: Overall Measure

	VCM no VCM			Std. Mean Difference				Std. Mean Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003 ·	- _
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	7.7%	-0.28 [-0.48, -0.09]	2007	_ —
Frosh 2008	27.95	13.45	153	30	10.77	151	6.9%	-0.17 [-0.39, 0.06]	2008	
Garvelink 2014 2	41.6	9.5	66	44.1	12.3	65	4.4%	-0.23 [-0.57, 0.12]	2014	
Kuppermann 2014	12.9	14.1	357	13.8	15.6	353	9.1%	-0.06 [-0.21, 0.09]	2014	
Garvelink 2014 1	43.6	14.2	70	40.9	11.6	70	4.6%	0.21 [-0.13, 0.54]	2014	
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017	
Epstein 2018	9.09	2.35	61	9.48	2.23	61	4.3%	-0.17 [-0.52, 0.19]	2018	
Hopkin 2019	14.59	15.04	122	23.13	20.34	136	6.4%	-0.47 [-0.72, -0.22]	2019	
Witteman 2020 6b	39	27	395	42	27	422	9.4%	-0.11 [-0.25, 0.03]	2020	
Witteman 2020 4b	35	28	350	42	27	422	9.2%	-0.25 [-0.40, -0.11]	2020	
Witteman 2020 6b + 6c	36	27	413	42	27	422	9.4%	-0.22 [-0.36, -0.09]	2020	
Witteman 2020 6c	36	26	440	42	27	422	9.5%	-0.23 [-0.36, -0.09]	2020	
Witteman 2020 6a	35	27	363	42	27	422	9.3%	-0.26 [-0.40, -0.12]	2020	
Total (95% CI)			3147			3322	100.0%	-0.20 [-0.29, -0.11]		◆
Heterogeneity: Tau ² = 0.0	2; Chi ² =	39.50,	df = 13	(P = 0.0	0002); l ^a	'= 67%				
Test for overall effect: Z =	4.35 (P	< 0.000	1)						-	Favours VCM Eavours no VCM

Figure 3b. Decisional Conflict by Type of Values Clarification Method

VCM no VCM Std. Mean Difference Std. Mean Difference	
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% Cl Year IV, Random, 95% Cl	
1.1.1 Decision analysis	
Montgomery 2003 27.6 12.1 100 38.9 18.3 112 5.7% -0.72 [-1.00, -0.44] 2003	
Montgomery 2007 23.6 15.1 198 27.8 14.6 201 7.7% -0.28 [-0.48,-0.09] 2007	
Hopkin 2019 14.59 15.04 122 23.13 20.34 136 6.4% -0.47 [-0.72, -0.22] 2019	
Witteman 2020 6b + 6c 36 27 413 42 27 422 9.4% -0.22 [-0.36, -0.09] 2020	
Witteman 2020 6c 36 26 440 42 27 422 9.5% -0.23 [-0.36, -0.09] 2020	
Subtotal (95% Cl) 1273 1293 38.6% -0.35 [-0.50, -0.20]	
Heterogeneity: Tau ² = 0.02; Chi ² = 12.96, df = 4 (P = 0.01); l ² = 69%	
Test for overall effect: Z = 4.58 (P < 0.00001)	
1.1.2 Rating scales	
Garvelink 2014 1 43.6 14.2 70 40.9 11.6 70 4.6% 0.21 F0.13 0.541 2014	
Garvelink 2014 2 41.6 9.5 66 44.1 12.3 65 4.4% -0.23 F0.57 0.12 2014	
Kuppermann 2014 12.9 14.1 357 13.8 15.6 353 9.1% -0.06 -0.21, 0.09 2014	
Witteman 2020 6a 35 27 363 42 27 422 9.3% -0.26 -0.40 -0.12 2020	
Subtotal (95% Cl) 856 910 27.4% -0.11 [-0.29, 0.07]	
Heterogeneity: Tau ² = 0.02; Chi ² = 8.30, df = 3 (P = 0.04); l ² = 64%	
Test for overall effect: Z = 1.20 (P = 0.23)	
1.1.3 Other	
$r_{rosb} = 0.008$ 27.95 13.45 153 30 10.77 151 6.9% -0.17.10.39 0.061 2008	
Shirk 2017 2.5 0.9 59 2.2 0.9 63 4.2% 0.33 F.0.3 0.691 2017	
Enstein 2018 9.09 2.35 61 9.48 2.23 61 4.3% -0.17 F0.52 0.19 2018	
Witteman 2020 4b 35 28 350 42 27 422 9.2% -0.25 F0.40 -0.11 2020	
Witteman 2020 6b 39 27 395 42 27 422 94% -0.11 F0.25 0.03 2020	
Subtotal (95% Cl) 1018 1119 34.0% -0.12 [-0.26, 0.03]	
Heterogeneity: Tau ² = 0.01; Chi ² = 9.38, df = 4 (P = 0.05); l ² = 57%	
Test for overall effect: Z = 1.58 (P = 0.11)	
Total (95% CI) 3147 3322 100.0% -0.20 [-0.29, -0.11]	
Heterogeneity: Tau ² = 0.02; Chi ² = 39.50; df = 13 (P = 0.0002); i ² = 67%	_
Test for overall effect Z = 4 35 (P < 0.0001)	1
Test for subgroup differences: Chi ² = 6.08. df = 2 (P = 0.05). I ² = 67.1%	M

Head-to-Head Evaluations of Values Clarification Methods

The five studies that compared values clarification methods to each other reported findings that align with the findings of our meta-analyses. Methods that provided users with explicit feedback regarding how the decision options align with their stated values led to somewhat better outcomes, including greater values congruence. [48] When asked to compare methods to each other, study participants also preferred a values clarification method that explicitly showed them how the decision options align with their stated values. [72] Different values clarification methods yielded different patterns of attribute importance. [59–61] Brief summaries of each study are available in Online Appendix 3.

Discussion

Overall, our systematic review and meta-analyses confirm that explicit values clarification methods improve decision outcomes, notably by increasing values congruence and decreasing decisional conflict. Patient decision aids should include an explicit values clarification method.

While the best explicit values clarification method may depend on context—for example, urgent versus routine care or the extent to which a decision has a clear set of decision attributes—our analyses suggest that patient decision aid developers may wish to consider methods that draw on multicriteria decision analysis. The apparent advantages of such methods shown in our analyses may reflect similarities between the process and the outcome. In other words, increased values congruence yielded by decision analytic methods may be a function of the ways in which such methods transparently show people how their options align with their stated values. We additionally caution that when these methods use pre-specified attributes, there might not be the

flexibility for users to add new attributes, highlighting the importance of research to inform attribute selection. We acknowledge that some researchers have argued that health professionals having an unhurried, highquality conversation with patients may be a preferred approach for at least some patients, especially when decision attributes are many and varied. However, in this systematic review, trials of Open Discussion values clarification methods did not demonstrate strong results, suggesting that such an ideal may be difficult to achieve.

To advance further knowledge on the merits and pitfalls of different values clarification methods, we recommend that authors of future trials of values clarification methods report four outcomes: decisional conflict, decision or decision intention, values congruence, and decisional regret. When possible, authors should make use of validated scales that have good psychometric properties and are commonly reported, as this facilitates evidence synthesis.

Decisional conflict should be assessed before people make the decision, using a version of the Decisional Conflict Scale. [75, 76] Decisions or decision intentions should be assessed when the decision is made.

Values congruence should be assessed once the decision is made. We acknowledge that including values congruence as an outcome brings both measurement and conceptual issues. Measurement issues exist because there are disagreements about how to measure what matters to people (or indeed, whether it is conceptually possible to do so) and compare such measures to what people choose. [77] Values congruence should not be measured using the values clarity subscale of the Decisional Conflict Scale, as this subscale measures perceived values clarity, not values congruence. [48] Further research is required to determine whether measuring values congruence might introduce bias or otherwise negatively influence decision making.

Decisional regret should be assessed with a version of the Decisional Regret Scale [78, 79] after people make the decision, ideally with a sufficiently long delay that longer-term effects can be captured. An included study in this review showed that a values clarification method reduced decisional regret, but only after a year had passed following implementation of the decision. [54]

For all four measures, authors should clearly report sample mean and sample standard deviation for continuous measures, numbers in each category for categorical measures, and sample size per study arm in all cases. Finally, we recommend that patient decision aid developers explain the rationale for their choice of values clarification method.

Our study has three main limitations. First, the included data were of moderate quality. Although this review includes many robust trials, the included studies often measured different outcomes or the same outcomes in different ways, there were missing data in some studies, some studies had high risk of bias (often because it was not possible to prevent study participants from ascertaining the study arm to which they were assigned), and some of our meta-analyses had high heterogeneity. Together, these issues suggest a degree of caution in our conclusions. Second, we did not distinguish between subtypes of values clarification methods. For example, different adaptive conjoint analysis exercises may be very different from each other, as might open discussions, or many other values clarification methods we grouped together, particularly those we grouped under the broad umbrella term of multicriteria decision analysis. Indeed, the values clarification methods used and trialed may simply reflect authors' interests and expertise. Given the breadth of methods available, further comparative effectiveness research is needed to conclusively determine the superiority of any given method. Third and finally, our primary findings were heavily influenced by studies conducted with relatively homogenous populations making hypothetical decisions. Although our sensitivity analyses suggested no differences

between studies in real and hypothetical contexts, we nonetheless believe further study is needed in more diverse populations making real decisions before drawing firmer conclusions.

Our study also has three main strengths. First, we catalog definitions and resources regarding values clarification methods, as well as recommended outcomes to report in studies. In doing so, we hope to offer more clarity and structure to a literature that can be confusing to navigate, particularly for those who are newer to developing patient decision aids. Second, we begin to answer a core question that commonly arises when developing a patient decision aid: when including a values clarification method, which type of method should one use? Third and finally, we used rigorous methods and an expansive, systematic search. By conducting a systematic review, we reduced our likelihood of missing relevant studies. By including meta-analyses, we offer stronger findings and recommendations than would be possible without pooling data across multiple studies.

In conclusion, patient decision aids should include an explicit values clarification method. Patient decision aid developers may wish to consider the potential advantages of multicriteria decision analysis. Future research should further investigate which methods lead to the best outcomes across or within particular decisions, populations, and settings. Authors of randomized controlled trials in this area should report decisional conflict, decision made, values congruence, and decisional regret.

DECLARATIONS

Abbreviations

None

Ethics Approval, Consent to Participate and Consent for Publication

Not applicable.

Availability of Data and Materials

Full data are available in the online appendices.

Competing Interests

None.

Funding

This study was funded by the Canadian Institutes of Health Research (CIHR) FDN-148426 (PI Witteman). HOW receives salary support from Tier 2 Canada Research Chair in Human-Centred Digital Health and received salary support during this study from a Fonds de Recherche du Québec-Santé (FRQS) Research Scholar Junior 2 Career Award. The CIHR, Canada Research Chairs program, and FRQS had no role in determining the study design, the plans for data collection or analysis, the decision to publish, nor the preparation of this manuscript.

Authors' Contributions

All authors contributed to the design of the study. HOW, RN, GV, SCD, SC, MM, TP, CR, CRB, JJ contributed to data collection. HOW, SCD, and JJ conducted data analysis and interpretation. HOW drafted the first version of the article with early revision by RN, GV, SCD, SC, MM, TP, CR, CRB, JJ and multiple subsequent revisions by all authors. All authors critically revised the article and approved the final version for submission for publication. HOW had full access to all the data in the study and had final responsibility for the decision to submit for publication. Authors BA, JFPB, SC, AF, TG, MM, AP, MP, TP, CR, DR, CRB, PT, MW, DBW, CEW contributed approximately equally and are listed alphabetically by last name.

Acknowledgements

The authors gratefully acknowledge Frédéric Bergeron, MLIS, for assistance with search strategy and Caroline Beaudoin for assistance in resolving article counts. We thank all authors of the original articles who generously gave their time to provide missing data when we were unable to extract the data needed from their papers.

References

- [1] Marteau TM, Dormandy E, Michie S. A measure of informed choice. *Health Expect* 2001; 4: 99–108.
- [2] Llewellyn-Thomas HA. Patients' health-care decision making: a framework for descriptive and experimental investigations. *Med Decis Making* 1995; 15: 101–106.
- [3] Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. *Health Aff* 2013; 32: 276–284.
- [4] Hoffmann TC, Montori VM, Del Mar C. The connection between evidence-based medicine and shared decision making. *JAMA* 2014; 312: 1295–1296.
- [5] Barrett B, McKenna P. Communicating benefits and risks of screening for prostate, colon, and breast cancer. *Fam Med* 2011; 43: 248–253.
- [6] Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. *BMJ* 2012; 345: e6572.
- [7] Llewellyn-Thomas HA, Crump RT. Decision support for patients: values clarification and preference elicitation. *Med Care Res Rev* 2013; 70: 50S–79S.
- [8] Munro S, Stacey D, Lewis KB, et al. Choosing treatment and screening options congruent with values: Do decision aids help? Sub-analysis of a systematic review. *Patient Educ Couns* 2016; 99: 491–500.
- [9] Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Epub ahead of print 2017. DOI: 10.1002/14651858.CD001431.pub5.
- [10] Peinado S, Paquin RS, Rini C, et al. Values clarification and parental decision making about newborn genomic sequencing. *Health Psychol*. Epub ahead of print 30 December 2019. DOI: 10.1037/hea0000829.
- [11] Witteman HO, Scherer LD, Gavaruzzi T, et al. Design Features of Explicit Values Clarification Methods: A Systematic Review. *Med Decis Making* 2016; 36: 453–471.
- [12] Witteman HO, Gavaruzzi T, Scherer LD, et al. Effects of Design Features of Explicit Values Clarification Methods: A Systematic Review. *Med Decis Making* 2016; 36: 760–776.
- [13] Bridges JFP, Brett Hauber A, Marshall D, et al. Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health 2011; 14: 403–413.
- [14] Ho M, Saha A, McCleary KK, et al. A Framework for Incorporating Patient Preferences Regarding Benefits and Risks into Regulatory Assessment of Medical Technologies. *Value Health* 2016; 19: 746–750.
- [15] Kristensen FB, Husereau D, Huić M, et al. Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA. Value in Health 2019; 22: 13–20.
- [16] O'Connor A, Llewellyn-Thomas H, Dolan J, et al. Section D: Clarifying and Expressing Values. In: O'Connor A, Llewellyn-Thomas H, Stacey D (eds) *IPDAS Collaboration Background Document*. International Patient Decision Aids Standards (IPDAS) Collaboration, 2005, pp. 17–23.
- [17] Fagerlin A, Pignone M, Abhyankar P, et al. Clarifying values: an updated review. *BMC Med Inform Decis Mak* 2013; 13 Suppl 2: S8.

- [18] Charles C, Gafni A. The vexing problem of defining the meaning, role and measurement of values in treatment decision-making. *J Comp Eff Res* 2014; 3: 197–209.
- [19] Lim C, Berry ABL, Hirsch T, et al. Understanding What Is Most Important to Individuals with Multiple Chronic Conditions: A Qualitative Study of Patients' Perspectives. J Gen Intern Med 2017; 32: 1278–1284.
- [20] Rocque R, Chipenda Dansokho S, Grad R, et al. What Matters to Patients and Families: A Content and Process Framework for Clarifying Preferences, Concerns, and Values. *Med Decis Making* 2020; 272989X20940660.
- [21] Patient Preference Information Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. Food and Drug Administration, https://www.fda.gov/media/92593/download (24 August 2016).
- [22] Pieterse AH, de Vries M, Kunneman M, et al. Theory-informed design of values clarification methods: a cognitive psychological perspective on patient health-related decision making. Soc Sci Med 2013; 77: 156–163.
- [23] de Vries M, Fagerlin A, Witteman HO, et al. Combining deliberation and intuition in patient decision support. *Patient Educ Couns* 2013; 91: 154–160.
- [24] Fischhoff B, Barnato AE. Value Awareness: A New Goal for End-of-life Decision Making. *MDM Policy & Practice* 2019; 4: 2381468318817523.
- [25] Ali S, Ronaldson S. Ordinal preference elicitation methods in health economics and health services research: using discrete choice experiments and ranking methods. *Br Med Bull* 2012; 103: 21–44.
- [26] Whitty JA, Lancsar E, Rixon K, et al. A systematic review of stated preference studies reporting public preferences for healthcare priority setting. *Patient* 2014; 7: 365–386.
- [27] Pieterse AH, Berkers F, Baas-Thijssen MCM, et al. Adaptive Conjoint Analysis as individual preference assessment tool: feasibility through the internet and reliability of preferences. *Patient Educ Couns* 2010; 78: 224–233.
- [28] Bansback N, Li LC, Lynd L, et al. Development and preliminary user testing of the DCIDA (dynamic computer interactive decision application) for 'nudging'patients towards high quality decisions. BMC Med Inform Decis Mak 2014; 14: 1–13.
- [29] Dolan JG, Boohaker E, Allison J, et al. Patients' preferences and priorities regarding colorectal cancer screening. *Med Decis Making* 2013; 33: 59–70.
- [30] Ungar WJ, Hadioonzadeh A, Najafzadeh M, et al. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. *Respir Med* 2014; 108: 842–851.
- [31] Thokala P, Devlin N, Marsh K, et al. Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 2016; 19: 1–13.
- [32] Regier DA, Peacock S. Theoretical Foundations of MCDA. In: Marsh K, Goetghebeur M, Thokala P, et al. (eds) *Multi-Criteria Decision Analysis to Support Healthcare Decisions*. Cham: Springer International Publishing, 2017, pp. 9–28.
- [33] Hazlewood GS, Marshall DA, Barber CEH, et al. Using a Discrete-Choice Experiment in a Decision Aid to Nudge Patients Towards Value-Concordant Treatment Choices in Rheumatoid Arthritis: A Proof-of-Concept Study. Patient Prefer Adherence 2020; 14: 829–838.

- [34] Weir KR, Bonner C, McCaffery K, et al. Pharmacists and patients sharing decisions about medicines: Development and feasibility of a conversation guide. *Res Social Adm Pharm* 2019; 15: 682–690.
- [35] Ottawa Personal Decision Guides Patient Decision Aids Ottawa Hospital Research Institute, https://decisionaid.ohri.ca/decguide.html (accessed 4 November 2020).
- [36] Masya LM, Young JM, Solomon MJ, et al. Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. *Dis Colon Rectum* 2009; 52: 1994–2002.
- [37] Heckerling PS, Verp MS, Albert N. Patient or physician preferences for decision analysis: the prenatal genetic testing decision. *Med Decis Making* 1999; 19: 66–77.
- [38] Jibaja-Weiss ML, Volk RJ. Utilizing computerized entertainment education in the development of decision aids for lower literate and naive computer users. *J Health Commun* 2007; 12: 681–697.
- [39] Stiggelbout AM, Kiebert GM, Kievit J, et al. Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. *Med Decis Making* 1994; 14: 82–90.
- [40] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6: e1000097.
- [41] Higgins JPT, Green S (eds). *Cochrane handbook for systematic reviews for interventions*, https://handbook-5-1.cochrane.org/front_page.htm (2011).
- [42] Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003; 327: 557–560.
- [43] de Achaval S, Fraenkel L, Volk RJ, et al. Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty. *Arthritis Care Res* 2012; 64: 229–237.
- [44] Fraenkel L, Rabidou N, Wittink D, et al. Improving informed decision-making for patients with knee pain. J Rheumatol 2007; 34: 1894–1898.
- [45] Hess LM, Litwiller A, Byron J, et al. Preference elicitation tool for abnormal uterine bleeding treatment: a randomized controlled trial. *Patient* 2015; 8: 217–227.
- [46] Hutyra CA, Smiley S, Taylor DC, et al. Efficacy of a Preference-Based Decision Tool on Treatment Decisions for a First-Time Anterior Shoulder Dislocation: A Randomized Controlled Trial of At-Risk Patients. *Med Decis Making* 2019; 39: 253–263.
- [47] Jayadevappa R, Chhatre S, Gallo JJ, et al. Treatment preference and patient centered prostate cancer care: Design and rationale. *Contemp Clin Trials* 2015; 45: 296–301.
- [48] Witteman HO, Julien A-S, Ndjaboue R, et al. What Helps People Make Values-Congruent Medical Decisions? Eleven Strategies Tested across 6 Studies. *Med Decis Making* 2020; 40: 266–278.
- [49] Myers RE. Value-based decision-making in prostate cancer early detection. DAMD17-98-1-8641, Thomas Jefferson University, November 2003.
- [50] Myers RE, Daskalakis C, Cocroft J, et al. Preparing African-American men in community primary care practices to decide whether or not to have prostate cancer screening. J Natl Med Assoc 2005; 97: 1143– 1154.
- [51] Shirk JD, Crespi CM, Saucedo JD, et al. Does Patient Preference Measurement in Decision Aids Improve Decisional Conflict? A Randomized Trial in Men with Prostate Cancer. *Patient*. Epub ahead of print 16

June 2017. DOI: 10.1007/s40271-017-0255-7.

- [52] Bekker HL, Hewison J, Thornton JG. Applying decision analysis to facilitate informed decision making about prenatal diagnosis for Down syndrome: a randomised controlled trial. *Prenat Diagn* 2004; 24: 265– 275.
- [53] Clancy CM, Cebul RD, Williams SV. Guiding individual decisions: a randomized, controlled trial of decision analysis. Am J Med 1988; 84: 283–288.
- [54] Feldman-Stewart D, Tong C, Siemens R, et al. The Impact of Explicit Values Clarification Exercises in a Patient Decision Aid Emerges After the Decision Is Actually Made. *Medical Decision Making* 2012; 32: 616–626.
- [55] Hopkin G, Au A, Collier VJ, et al. Combining Multiple Treatment Comparisons with Personalized Patient Preferences: A Randomized Trial of an Interactive Platform for Statin Treatment Selection. *Med Decis Making* 2019; 39: 264–277.
- [56] Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. Br J Gen Pract 2003; 53: 446– 453.
- [57] Montgomery AA, Emmett CL, Fahey T, et al. Two decision aids for mode of delivery among women with previous caesarean section: Randomized controlled trial. *BMJ: British Medical Journal* 2007; 334: 1305– 1309.
- [58] Witteman HO, Chipenda Dansokho S, Exe N, et al. Risk Communication, Values Clarification, and Vaccination Decisions. *Risk Anal* 2015; 35: 1801–1819.
- [59] Brenner A, Howard K, Lewis C, et al. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia. J Gen Intern Med 2014; 29: 507– 513.
- [60] Pignone MP, Brenner AT, Hawley S, et al. Conjoint analysis versus rating and ranking for values elicitation and clarification in colorectal cancer screening. *J Gen Intern Med* 2012; 27: 45–50.
- [61] Pignone MP, Howard K, Brenner AT, et al. Comparing three techniques for eliciting patient values for decision making about prostate-specific antigen screening: a randomized controlled trial. JAMA Intern Med 2013; 173: 362–368.
- [62] Au DH, Udris EM, Engelberg RA, et al. A randomized trial to improve communication about end-of-life care among patients with COPD. *Chest* 2012; 141: 726–735.
- [63] Epstein AS, O'Reilly EM, Shuk E, et al. A Randomized Trial of Acceptability and Effects of Values-Based Advance Care Planning in Outpatient Oncology: Person-Centered Oncologic Care and Choices. J Pain Symptom Manage 2018; 56: 169–177.e1.
- [64] Kennedy ADM, Sculpher MJ, Coulter A, et al. Effects of Decision Aids for Menorrhagia on Treatment Choices, Health Outcomes, and Costs: a randomized controlled trial. *JAMA* 2002; 288: 2701.
- [65] Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. *J Natl Cancer Inst* 1997; 89: 148–157.
- [66] Matheis-Kraft C, Roberto KA. Influence of a values discussion on congruence between elderly women and their families on critical health care decisions. *J Women Aging* 1997; 9: 5–22.
- [67] Abhyankar P, Bekker HL, Summers BA, et al. Why values elicitation techniques enable people to make informed decisions about cancer trial participation. *Health Expect* 2011; 14 Suppl 1: 20–32.

- [68] O'Connor RN AM, Wells GA, Frcp PTMD, et al. The effects of an 'explicit' values clarification exercise in a woman's decision aid regarding postmenopausal hormone therapy. *Health Expectations* 1999; 21–32.
- [69] Paquin RS, Peinado S, Lewis MA, et al. A behavior-theoretic evaluation of values clarification on parental beliefs and intentions toward genomic sequencing for newborns. *Soc Sci Med* 2018; 112037.
- [70] Garvelink MM, ter Kuile MM, Stiggelbout AM, et al. Values clarification in a decision aid about fertility preservation: does it add to information provision? *BMC Med Inform Decis Mak* 2014; 14: 68.
- [71] Kuppermann M, Pena S, Bishop JT, et al. Effect of enhanced information, values clarification, and removal of financial barriers on use of prenatal genetic testing: a randomized clinical trial. JAMA 2014; 312: 1210– 1217.
- [72] Feldman-Stewart D, Brennenstuhl S, Brundage MD, et al. An explicit values clarification task: development and validation. *Patient Educ Couns* 2006; 63: 350–356.
- [73] Sheridan SL, Griffith JM, Behrend L, et al. Effect of adding a values clarification exercise to a decision aid on heart disease prevention: a randomized trial. *Med Decis Making* 2010; 30: E28–39.
- [74] Frosch D, Bhatnagar V, Tally S, et al. Internet patient decision support. *Arch Intern Med* 2008; 168: 363–369.
- [75] O'Connor AM. User Manual Decisional Conflict Scale. University of Ottawa, https://decisionaid.ohri.ca/docs/develop/User_Manuals/UM_Decisional_Conflict.pdf (2010).
- [76] Decisional conflict scale evaluation measures patient decision aids Ottawa hospital research institute, https://decisionaid.ohri.ca/eval_dcs.html (accessed 20 January 2021).
- [77] Winn K, Ozanne E, Sepucha K. Measuring patient-centered care: An updated systematic review of how studies define and report concordance between patients' preferences and medical treatments. *Patient Educ Couns* 2015; 98: 811–821.
- [78] Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. *Med Decis Making* 2003; 23: 281–292.
- [79] Decision regret scale evaluation measures patient decision aids Ottawa hospital research institute, https://decisionaid.ohri.ca/eval_regret.html (accessed 20 January 2021).

Online Appendix 1: Search Strategies

- #1 ((value? OR patient preference? OR treatment preference?) adj5 (clarif* OR elicit*)).ti,ab,kw
- #2 (Decision Making/ AND Social Values/)
- **#3** MCDA.ti,ab
- #4 analytical hierarchy process.ti,ab,kw
- **#5** best-worst scaling.ti,ab,kw
- #6 ((conjoint OR decision) adj3 analysis):ti,ab,kw
- **#7** data envelopment analysis.ti,ab,kw
- **#8** Decision conferencing.ti,ab,kw
- **#9** Decision models.ti,ab,kw
- **#10** direct rating.ti,ab,kw
- **#11** points allocation.ti,ab,kw
- **#12** discrete choice experiment.ti,ab ,kw
- **#13** ("dominance-based" adj3 approach*).ti,ab,kw
- **#14** EVIDEM framework.ti,ab,kw
- **#15** (geometrical analysis for interactive aid OR GAIA).ti,ab,kw
- **#16** MACBETH.ti,ab,kw
- **#17** ("Measuring Attractiveness" adj4 "Categorical Based Evaluation TecHnique").ti,ab,kw
- **#18** Multi-Attribute Global Inference of Quality.ti,ab,kw
- #19 (("Multiple attribute" OR "multiple criteria" OR multiattribute) adj2 (utility OR theory OR analysis)).ti,ab,kw
- **#20** (MAUT OR MAVT OR MCUA OR MCA).ti,ab,kw
- #21 ("Novel approach to imprecise assessment and decision environments" OR NAIADE).ti,ab,kw
- #22 ORESTE.ti,ab,kw
- **#23** Pairwise comparisons.ti,ab,kw
- #24 PAPRIKA.ti,ab,kw
- **#25** Pairwise RanKings.ti,ab,kw
- **#26** PROMETHEE.ti,ab,kw
- **#27** Preference Ranking Organization Method for Enrichment of Evaluations.ti,ab,kw
- #28 QUALItative FLEXible.ti,ab,kw
- #29 Simple Multi Attribute Rating Technique.ti,ab,kw
- **#30** SMART.ti,ab,kw
- **#31** Standard gamble.ti,ab,kw
- **#32** Swing weighting.ti,ab,kw
- **#33** TOPSIS.ti,ab,kw

- **#34** Technique for Order Preference by Similarity to the Ideal Solution.ti,ab,kw
- **#35** (Time tradeoff OR time tradeoff).ti,ab ,kw
- **#36** Value function methods.ti,ab,kw
- **#37** Valutazione delle Tecnologie Sanitarie.ti,ab,kw
- **#38** VDA.ti,ab,kw
- **#39** VTS.ti,ab,kw
- **#40** verbal decision analysis.ti,ab,kw
- #41 visual analog scale.ti,ab,kw
- **#42** willingness-to-pay.ti,ab,kw
- **#43** ((Scoring OR weighting) adj1 methods).ti,ab,kw
- #44 REGIME.ti,ab,kw
- #45 (scal* adj2 (methods OR Natural OR Constructed OR Objective)).ti,ab,kw
- **#46** OR/3-45
- #47 Randomized Controlled Trials as Topic/
- #48 randomized controlled trial/
- #49 Random Allocation/
- **#50** Double Blind Method/
- **#51** Single Blind Method/
- #52 clinical trial/
- **#53** clinical trial, phase i.pt
- **#54** clinical trial, phase ii.pt
- **#55** clinical trial, phase iii.pt
- **#56** clinical trial, phase iv.pt
- **#57** controlled clinical trial.pt
- **#58** randomized controlled trial.pt
- **#59** multicenter study.pt
- #60 clinical trial.pt
- #61 exp Clinical Trials as topic/
- #62 (clinical adj trial\$).tw
- #63 ((singl\$ or doubl\$ or treb\$ or tripl\$) adj (blind\$3 or mask\$3)).tw
- #64 PLACEBOS/
- #65 placebo\$.tw
- #66 randomly allocated.tw

- **#67** (allocated adj2 random\$).tw
- **#68** OR/47-67
- **#69** (#1 OR #2 OR #46) AND #68
- **#70** #70 NOT (animals/ NOT humans/)

- #1 ((value* OR "patient preference" OR "treatment preferences") NEAR/5 (clarif* OR elicit*)):ti,ab,kw
- #2 'decision support system'/de OR 'patient decision making'/de
- **#3** MCDA:ti,ab,kw
- #4 "analytical hierarchy process":ti,ab,kw
- **#5** "best-worst scaling":ti,ab,kw
- #6 ((conjoint OR decision) NEAR/3 analysis):ti,ab,kw
- **#7** "data envelopment analysis":ti,ab,kw
- **#8** "Decision conferencing":ti,ab,kw
- **#9** "Decision models":ti,ab,kw
- **#10** "direct rating":ti,ab,kw
- **#11** "points allocation":ti,ab,kw
- **#12** "discrete choice experiment":ti,ab,kw
- **#13** ("dominance-based" NEAR/3 approach*):ti,ab,kw
- **#14** "EVIDEM framework":ti,ab,kw
- **#15** "geometrical analysis for interactive aid OR GAIA":ti,ab,kw
- **#16** MACBETH:ti,ab,kw
- **#17** ("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique"):ti,ab,kw
- **#18** "Multi-Attribute Global Inference of Quality":ti,ab,kw
- #19 (("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis)):ti,ab,kw
- #20 (MAUT OR MAVT OR MCUA OR MCA):ti,ab,kw
- **#21** ("Novel approach to imprecise assessment and decision environments" OR NAIADE):ti,ab,kw
- #22 ORESTE:ti,ab,kw
- **#23** "Pairwise comparisons":ti,ab,kw
- **#24** PAPRIKA:ti,ab,kw
- **#25** "Pairwise RanKings":ti,ab,kw
- **#26** PROMETHEE:ti,ab,kw
- **#27** "Preference Ranking Organization Method for Enrichment of Evaluations":ti,ab,kw
- **#28** "QUALItative FLEXible":ti,ab,kw
- **#29** "Simple Multi Attribute Rating Technique":ti,ab,kw
- **#30** SMART:ti,ab,kw
- **#31** "Standard gamble":ti,ab,kw
- **#32** "Swing weighting":ti,ab,kw
- **#33** TOPSIS:ti,ab,kw

- **#34** "Technique for Order Preference by Similarity to the Ideal Solution":ti,ab,kw
- **#35** ("Time tradeoff" OR "time tradeoff"):ti,ab,kw
- **#36** "Value function methods":ti,ab,kw
- **#37** "Valutazione delle Tecnologie Sanitarie":ti,ab,kw
- **#38** VDA:ti,ab,kw
- #39 VTS:ti,ab,kw
- #40 "verbal decision analysis":ti,ab,kw
- #41 "visual analog scale":ti,ab,kw
- **#42** "willingness-to-pay":ti,ab,kw
- **#43** ((Scoring OR weighting) NEAR/1 methods):ti,ab,kw
- #44 REGIME:ti,ab,kw
- #45 (scal* NEAR/2 (methods OR Natural OR Constructed OR Objective)):ti,ab,kw
- #46 #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #
- #47 'clinical trial'/de
- **#48** 'randomized controlled trial'/de
- #49 'randomization'/de
- **#50** 'single blind procedure'/de
- **#51** 'double blind procedure'/de
- **#52** 'crossover procedure'/de
- **#53** 'placebo'/de OR 'prospective study'/de
- **#54** (randomi?ed NEXT/1 controlled NEXT/1 trial):ab,ti
- **#55** rct:ab,ti OR 'random allocation':ab,ti
- #56 'randomly allocated':ab,ti OR 'allocated randomly':ab,ti
- **#57** (allocated NEAR/2 random):ab,ti
- **#58** ((single OR double OR treble OR triple) NEXT/1 blind*):ab,ti
- **#59** placebo*:ab,ti
- **#60** #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59
- **#61** (#1 OR #2 OR #46) AND #60
- #62 #61 NOT (animal:de NOT human:de)
- #63 [embase]/lim NOT ([embase]/lim AND [medline]/lim)

- #1 ((value* OR "patient preference*" OR "treatment preference*") NEAR/5 (clarif* OR elicit*)):ti,ab
- #2 ("Decision Making":kw AND "Social Values":kw)
- **#3** MCDA:ti,ab
- #4 "analytical hierarchy process":ti,ab
- **#5** best-worst scaling:ti,ab
- #6 ((conjoint OR decision) NEAR/3 analysis):ti,ab
- **#7** "Decision conferencing":ti,ab
- **#8** "Decision models":ti,ab
- **#9** "direct rating":ti,ab
- **#10** "points allocation":ti,ab
- **#11** "discrete choice experiment":ti,ab
- **#12** ("dominance-based" NEAR/3 approach*):ti,ab
- **#13** "Elimination and Choice Expressing Reality":ti,ab
- **#14** "EVIDEM framework":ti,ab
- **#15** "geometrical analysis for interactive aid" OR GAIA:ti,ab
- **#16** MACBETH:ti,ab
- **#17** ("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique"):ti,ab
- **#18** "Multi-Attribute Global Inference of Quality":ti,ab
- **#19** "multiattribute objective function specification":ti,ab
- #20 (("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis)):ti,ab
- #21 (MAUT OR MAVT OR MCUA OR MCA):ti,ab
- **#22** ("Novel approach to imprecise assessment and decision environments" OR NAIADE):ti,ab
- #23 ORESTE:ti,ab
- **#24** "Pairwise comparisons":ti,ab
- #25 PAPRIKA:ti,ab
- **#26** "Pairwise RanKings":ti,ab
- **#27** PROMETHEE:ti,ab
- **#28** "Preference Ranking Organization Method for Enrichment of Evaluations":ti,ab
- **#29** "QUALItative FLEXible":ti,ab
- **#30** "Simple Multi Attribute Rating Technique":ti,ab
- **#31** SMART:ti,ab
- **#32** "Standard gamble":ti,ab
- **#33** "Swing weighting":ti,ab

- **#34** TOPSIS:ti,ab
- **#35** "Technique for Order Preference by Similarity to the Ideal Solution":ti,ab
- **#36** ("Time tradeoff" OR "time tradeoff"):ti,ab
- **#37** "Value function methods":ti,ab
- **#38** "Valutazione delle Tecnologie Sanitarie":ti,ab
- **#39** VDA:ti,ab
- #40 VTS:ti,ab
- #41 "verbal decision analysis":ti,ab
- #42 "visual analog scale":ti,ab
- **#43** "willingness-to-pay":ti,ab
- **#44** scoring method*:ti,ab OR "weighting method*":ti,ab
- #45 REGIME:ti,ab
- #46 (scal* NEAR/2 (methods OR Natural OR Constructed OR Objective)):ti,ab
- **#47** {OR #3-#46}
- **#48** #1 OR #2 OR #47

- **#1** TS=(((value\$ OR "patient preference\$" OR "treatment preference\$") NEAR/5 (clarif* OR elicit*)))
- **#2** TS=((conjoint OR decision) NEAR/3 analysis)
- #3 TS=(MCDA)
- #4 TS=("analytical hierarchy process")
- **#5** TS=("best-worst scaling")
- #6 TS=("data envelopment analysis")
- **#7** TS=("Decision conferencing")
- #8 TS=("Decision models")
- **#9** TS=("direct rating")
- **#10** TS=("points allocation")
- **#11** TS=("discrete choice experiment")
- **#12** TS=("dominance-based" NEAR/3 approach*)
- **#13** TS=("Elimination and Choice Expressing Reality")
- #14 TS=("EVIDEM framework")
- **#15** TS=("geometrical analysis for interactive aid" OR GAIA)
- **#16** TS=(MACBETH)
- **#17** TS= ("Measuring Attractiveness" NEAR/4 "Categorical Based Evaluation TecHnique")
- **#18** TS=("Multi-Attribute Global Inference of Quality")
- **#19** TS=(("Multiple attribute" OR "multiple criteria" OR multiattribute) NEAR/2 (utility OR theory OR analysis))
- **#20** TS=(MAUT OR MAVT OR MCUA OR MCA)
- #21 TS=("Novel approach to imprecise assessment and decision environments" OR NAIADE)
- #22 TS=(ORESTE)
- **#23** TS=("Pairwise comparisons")
- #24 TS=(PAPRIKA)
- #25 TS=("Pairwise RanKings")
- #26 TS=(PROMETHEE)
- **#27** TS=("Preference Ranking Organization Method for Enrichment of Evaluations")
- #28 TS=("QUALItative FLEXible")
- **#29** TS=("Simple MultiAttribute Rating Technique")
- **#30** TS=(SMART)
- **#31** TS=("Standard gamble")
- #32 TS=(TOPSIS)
- **#33** TS=("Technique for Order Preference by Similarity to the Ideal Solution")

- **#34** TS=("time tradeoff" OR "time tradeoff")
- **#35** TS=("Value function methods")
- **#36** TS=("Valutazione delle Tecnologie Sanitarie")
- **#37** TS=(VDA)
- **#38** TS=(VTS)
- **#39** TS=("verbal decision analysis")
- #40 TS=("visual analog scale")
- **#41** TS=("willingness-to-pay")
- **#42** TS= ((Scoring OR weighinng) NEAR/1 methods)
- #43 TS=(REGIME)
- #44 TS=(scal* NEAR/2 (methods OR Natural OR Constructed OR Objective))
 #44 OR #43 OR #42 OR #41 OR #40 OR #39 OR #38 OR #37 OR #36 OR #35 OR #34 OR #33 OR #32 OR #31 OR #30 OR #29 OR #28 OR
 #27 OR #26 OR #25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR
- **#45** #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4 OR #3 OR #2
- #46 "clinical trial"
- #47 randomization
- #48 "crossover procedure"
- #49 placebo
- **#50** "prospective study"
- **#51** (randomi\$ed NEAR/1 "controlled trial")
- **#52** rct
- **#53** (allocat* NEAR/2 random*)
- **#54** ((single OR double OR treble OR triple) NEAR/1 blind*))
- **#55** #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 #54
- **#56** (#1 OR #45) AND #55

- **#1** TI ((value# OR "patient preference#" OR "treatment preference#") N5 ((clarif* OR elicit*))
- #2 AB ((value# OR "patient preference#" OR "treatment preference#") N5 ((clarif* OR elicit*))
- **#3** MH "Values Clarification"
- #4 MM "Decision Support Techniques"
- **#5** TI ((conjoint OR decision) N3 analysis) OR AB ((conjoint OR decision) N3 analysis)
- #6 TI MCDA OR AB MCDA
- **#7** TI "analytical hierarchy process" OR AB "analytical hierarchy process"
- **#8** TI "best-worst scaling" OR AB "best-worst scaling"
- #9 TI "data envelopment analysis" OR AB "data envelopment analysis"
- **#10** TI "Decision conferencing" OR AB "Decision conferencing"
- **#11** TI "Decision models" OR AB "Decision models"
- **#12** TI "direct rating" OR AB "direct rating"
- **#13** TI "points allocation" OR AB "points allocation"
- **#14** TI "discrete choice experiment" OR AB "discrete choice experiment"
- **#15** TI ("dominance-based" N3 approach*) OR AB ("dominance-based" N3 approach*)
- **#16** TI "Elimination and Choice Expressing Reality" OR AB "Elimination and Choice Expressing Reality"
- **#17** TI "EVIDEM framework" OR AB "EVIDEM framework"
- **#18** TI "geometrical analysis for interactive aid" OR GAIA OR AB "geometrical analysis for interactive aid" OR GAIA
- **#19** TI MACBETH OR AB MACBETH
- #20 TI ("Measuring Attractiveness" N4 "Categorical Based Evaluation TecHnique") OR AB ("Measuring Attractiveness" N4 "
- #21 TI (("Multiple attribute" OR "multiple criteria" OR multiattribute) N2 (utility OR theory OR analysis)) OR AB (("Multiple
- #22 TI (MAUT OR MAVT OR MCUA OR MCA) OR AB (MAUT OR MAVT OR MCUA OR MCA)
- **#23** TI ORESTE OR AB ORESTE
- **#24** TI "Pairwise comparisons" OR AB "Pairwise comparisons"
- #25 TI PAPRIKA OR AB PAPRIKA
- #26 TI "Pairwise RanKings" OR AB "Pairwise RanKings"
- #27 TI SMART OR AB SMART
- #28 TI "Standard gamble" OR AB "Standard gamble"
- **#29** TI "Swing weighting" OR AB "Swing weighting"
- **#30** TI TOPSIS OR AB TOPSIS
- **#31** TI "Technique for Order Preference by Similarity to the Ideal Solution" OR AB "Technique for Order Preference by Simi
- **#32** TI ("Time tradeoff" OR "time tradeoff") OR AB ("Time tradeoff" OR "time tradeoff")
- **#33** TI VDA OR AB VDA

- **#34** TI VTS OR AB VTS
- **#35** TI "visual analog scale" OR AB "visual analog scale"
- **#36** TI "willingness-to-pay" OR AB "willingness-to-pay"
- **#37** TI Scoring OR "weighting method#" OR AB Scoring OR "weighting method#"
- **#38** TI REGIME OR AB REGIME
- #39 TI (scal* N2 (methods OR Natural OR Constructed OR Objective)) OR AB (scal* N2 (methods OR Natural OR Constructe
- **#40** (S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR
- **#41** TX allocat* random*
- #42 MH "Quantitative Studies"
- #43 MH "Placebos"
- #44 TX placebo*
- #45 TX random* allocat*
- #46 MH "Random Assignment"
- **#47** TX randomi* control* trial*
- **#48** TX ((singl* n1 blind*) OR (singl* n1 mask*))
- **#49** TX ((doubl* n1 blind*) OR (doubl* n1 mask*))
- **#50** TX ((tripl* n1 blind*) OR (tripl* n1 mask*))
- **#51** TX ((trebl* n1 blind*) or (trebl* n1 mask*))
- **#52** TX (clinic* n1 trial*)
- **#53** PT "Clinical trial"
- **#54** MH "Clinical Trials+"
- **#55** #52 OR #65
- **#56** (#1 OR #2 OR #3 OR #4 OR #40) AND #55

ACTUAL Paper 20 (weile lost)	Corresponding or lati name (weile leve)	alar Correpoidig adar To real (w (wining)	r al pub. Title in naméleo ((nelle leu))	Castrol O Castrol O Castrol C Castrol Constraints C Castrol Constraints C C C Constraints C C C Constraints C C C C Constraints C C C C Constraints C C C C C C C C C C C C C C C C C C C	htime. 1 - channing in take option or out; 2 - channing brivers incore more plan: 3 - channing in take option or out; XE channing brivers incore more plan;	Number of options — Details (weite number) — (weite test	Type - L + ready - 2 = hypothes - 3 = number	China control (websited)	VCM Throny, framework of mathetyling mechanic reported in the paper (write text)	 Patina ka BA In (wite inst, e.g. in a BA lefts also or between information unition, in a cognitive inf, o 	Noda m, (mitrina) mitri	Type (using the Wittenam classification)	eid TIFE(br sammey & an paper)	rin Xubiyy	Type (short version) (weier inst, regr gaste what is, regilabily reperiod in the pa	Type (long weekin) (weine inst, copy paste what is explicitly respected in the paper)	Trainells Proc (ap) (1) - Regionity (2) - Regionity (3) - Regi	estation of evalue formentation Ten-prior devident and ten-prior devident ten-prior devid	Population Av (weiler local)	Total Total Kangle Kangle dan diar (weile (commonic) anniher)	Type(s) dicomparison(s) Con reference in realizations of VCMs (unit (units test)	queisan Kanamary of Badings (a trai) (antite trai)
Abbyodor 200	Abhyodar	perceditysilectrons exit	200 Way salaw chanten in a happen media penju maka da anali da kata pinar anar tida pengingkan pengin pengingkan pengin pengingkan pengingkan pengin pengingkan pe	<u> </u>	I sadar 1	2 Cataba (Sanahari Sanahari Sanahari Sanahari Sanahari Sanahari Sanahari Sanahari	en kong poar in ge kaloni w general same	3 Gauer-heast	VSI do do por prior 1999 do 2000 presenta por altra presenta por altra	 March American Conference of Conference 	nat Papar Salat d	Pinn and even	Per ad Ces	kany	The class dataset uses to a structure oper burgers of the class of the	m) Reverse of the second se	. 441 3	Tablet I hdqudady	Helday waves e.got 8 Feb 2016 (1999) and 1999 (1999) 10 (1999) and 1999 (1999) and 1999 10 (1999) and 1999 (1999) 10 (1999) and 1999 (1999) and 1999 (1999) and 1999 (1999) 10 (1999) and 1999 (1999) and 1999 (1999) and 1999 (1999) and 1999 (1999) 10 (1999) and 1999	30	So CHArgenerative So CHArgenerative VCM Parameter NCM Parameter	Amend a We want of the state of the state of the state
An 262	An .	Deal Art#3A ger	202 A Kundonized Yad in Inprove Communication, Urban Tal of Life Care Among Patrons Web COPD		,	3 Nameron Personalg and a fills for a small advance or patient op and facility or a small of the source field op and reserve for the source of the source for the source of the source of the reserve of the source of the source of the reserve of the source of the so	daman far am (sa diriter lasina almut eplaning, diriteration, an ke ina almut mil, performan servelamind and dar	i langdorae - COR	RD Besidespaire dan	ny nia meralita	Yebd (and comprise generated paper leads from).	List of concess.	List of Concess	Ensues only	A new page partiest specific facultural interdent partients are and shared with first samplet(s).	ierenii Geo progr pairine aprovile inclinate konceptoroiding the pairine's there must important professions the main of life reperiesces shat can be reversioned and shaned with dark sumption).		 Independently with research acceleration available to accion. 	Potoes with CDID (and show-line ine.)	34	Na VCM (sound) vs Ge VCM (nevening) vs ne dir dir dir dir dir dir dir dir dir dir	ner sachneised stad g statisfiel stadius glangsmohnen perfension te serentis er grenge mentis er grenge terste ser grenge
Bellev 201	Biller	kibilerFireb a ak	2004 Applying deviates analysis to facilitate informed deviate making already promoti depresent the Ones syntheses a mathematical contended and	. 3		1 2 Wheney possible Dom spin	nti tolare a panà lor ma	1 Dennis overlag Denn syndrom	- Independent regentent, utility-showy (BES).	nis an a DA	Yashal junisanow wa then isanashida and anizid and computer banad phendual goapi	n Makharolomid	Brokim Andysk	Doubles and pub	A distribution for and with all prompts, and a functional graph,	A doubline inter representing test-reprisem and protocopy encourses a collect protocopy efficiency a global utility (in due banknes print herizog a due banknes of herizog a solid with Brown cyndemse and idea of pregnency instantiani, and a disensitied graph integrating the wilky and MOR and figure to itshelidy the	I	i Vikamurke	Perguant source motiving a same problem material series sourceing result (index 2.1 in 200).	20. 117 working complete data for 206	No VCM (requires Res remarkation) vo VCM (require indexistic vo rem devices and oppin community) of the second sec	dentated extended drings with two table of the second seco
Bernier 2014 (1 el 7)	lesser	alam berner Four ole	2013 Comparing Yildon Gardharino Michael in Columna Channe Barrang Gardharino Marga A Francisco Marga and Chan Annunin		,	2 8 Windows on sciences of sciences of	mar tabu yadanatal algan, ula samata samata samata fan fan fan fan fan fan fan fan fan fa	1 George and second	 No specific densy se liner rest mensioned action 	r Aller beloweiten socher de	na Galar Ind	Rating scales	Raing and scaling	Rong and cooling	Keing a set of Day students and dist unlargelar and lapped at two students.	reproducible. Reach provide a stability of the stability	·	á helepedesty	Participants, aged 20 to 21 years (solitor parel) at arrange rick (as an errorge rick (as an errorge rick (as an error) at a soliton of control control.	34	Constitutes VCMa. Pro- butines advants (regilitation) maring and analysis of the second (regilitation) and and (regilitation) (regilitation) advants and (regilitation) advants advants advants (regilitation) advants advants advants (regilitation) advants advants advants (regilitation) advants advants (regilitation) advants advants (regilitation) advants (regilitatio	Alpana yan Janadi on ya Wang ang Mang ang Man
Berner 2014 (3 el 3)	lesser	dan basar tanak	2013 Computing Yildam Gardharam Belanda the Colonical Garden Bernung, Orienton Balang, and Bernung, Colonical and Colonia Assemble.			5 % Weshers a science of science of sciences of sci	me talan reducendi 30 pro, ohan wins mer (2) anning tala simulat food forwing, 975 juna me like CT 191	i Georgenia	Barrie Geier And	dyn Aller blometin sociae ab algonae denodosogy and e	nat Online Sailt	Math here i smith	Denter Geint Equipmen	a Disarti dalar opriana	Casjan (dison okin)	Bayester Christe Experiment respondents some allektion samplite autoris allektion balande allektion allektion hande allektion allektion allektion hyperkensiska allektion alle som at antidenses and allektion alle som at attraktionen alle solver soltaka disease antidenses. The brother disease antidenses. The brother disease antidenses. The brother disease along particular solution allektion and antidenses and allektion and allektion and approxime.		á halgonávely	Participants, agud 80 to 73 yront (yndich partic), at yront (yndich partic), at yrontaelan tionly holosyn gerentaelan tionly holosyn generatien tion	24	Can of down WMA: Poor hadron action implicity on aning and analogy in the population of the second second population of the second second population of the second second population of the second sec	signato sont distribution constraints and c
Gary 888	(lang		(B) Gang John Zuler, A. Gang San, J. S. San, J. S. San, J. San, J. San, J. San, S. San, San, S. San, S. San, S. San, S. San, San, San, San,			2 4 Chene-he option a second second second academy to constrain the second academy to constraints and the second second second academy to second second second second second academy to second second second second academy to second second second second second academy to second second second second second academy to second second second second second second academy to second second second second second second academy to second second second second second second academy to second second second second second second second academy to second second second second second second second second academy to second second second second second second second second second academy to second second second second second second second second second second academy to second second	men danar mang rakakar (konstru senten senten danar by danag bar danar by danar dan	1 Vacanas depa	din B. Danisa andya	Aller skingering derer der andelikige i die vanzen an inderering aller der der begrecht i B	Paper and compare () is sensed for sense of the sense matrix ()	Mah kecimuki	Becken Andreh	Beskins andpok	Non-series probability in the new year solution of the series of the ser	Barta Boshim and yan Jung Yu Y		1 halpsaholt of all	 Readous and loady physicase, etch Brophil with Viscoury of Promphases 		No contrast (second re definition and yre (MCM + indication and yre (MCM + indication) (MCM + indication) (An and a characteristic physical sector and physical sector and physi
do Auberral 2012	Inere Alwer	a daag ii ahada	(B) Support of the output of the State Research of the State State Analogue of the State State Analogue of the State State Analogue of the State State State State State State State State State State State State State Analogue of the State State State State Analogue of the State State State State State Analogue of the State State State State State State Analogue of the State State State State State State Analogue of the State State State State State State State Analogue of the State State State State State State State State State Analogue of the State Stat			1 2 Wardner ward ite opprove website w	ana ta bar ana (baran (baran) and danagen ya and danagen ya	i Kere estenditik	(DA) Gaple andys	Aller warding installing a vitit hander IA	ier Company hood	Mak koolood	Adaptor Cognot Analys	a Adaptiroongan andpa	Angeles regions angles (UCS)	any when values hadron of the second		I kalpadarlı klima anında kada az entekteri	ng Petinin sikikaro DA aby akaganal wika s sakigupk		belowsing only (second) Real vs (RA andy yields) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second) (second)	An and a model and
Epozeia 2018	Ipons	specifical makes ong	2023 A Fundament Third Acceptability and History of Material Acceptance Decemponent Care Processing Conceptance Decemponent Care Processing Conceptance and Dataset			2 Manerous Personalgi end et like ventilent probaging probaging probaging thataster that and the analytic diseased thataster that are CP are analytic diseased that are CP are analytic diseased that are CP are analytic and analytic and analytic and analytic and analytic analytic	internants for and LCPR and LCPR and the and the glass for any model of the former and the glass for any model on any model on a poly of the column poly of the poly of the po	1 George partner	wind Rehericalsoftware Generation and Advise Hereitand Michine Rehericand Hills Mic	Aller suching as information reg. can video inter- and	nal Tobaljaarrano	List of concerns (herevire)) Lis d'Onorm	Doors why	kannine (H quotine) flowing on goals, consense and some of organi.	endopera el californi Terre 118 ecceleratoria de la constante activitaria de descharta de descharta de la constante de descharta de la constante de la constante de la constante endoperante de la constante endoperante de la constante de la constante de la constante de la		2 Web a worked of the mound-inner	English-spealing parimen speal 22 pears or other with advanced protocolor other speak of the speak protocolor other speak of the speak parimeters of the speak of	W Hi was an analy a manufact (when anyl- was);	Unsel-our jos viles li akarvez vilen vieningiro VEM al un od vilen (polas kiervier wile) are gala kiervier wile) are gala kiervier blan da kiervier blan da kiervier blan da kiervier vien	damod somefall. The roken should in takk postportunit. Advanced Cor Plansing constraints 213 (b) PCCC interviewing the coupling PCCC interviewing the source of takk of the roken sub- rum machany and the source of takk of the roken sub- rum machany in the roken sub- rum machan
Polinas. Sovant 200	. Polose-Jeros	Ad Addama.	300. Ar opfar vilne skilletin sak Derbywer od okłate		,	a Chan be gina A gina A wita a kan be kan be	ne flore smith sold y singer that sold y singer that sold y sold y sold y sold y sold y sold y sold y sold y sold y sold y y y y i	3 Gaun pande	Behrmalleriner mehrlig für allebre allebre die dieser demonischer nicht	Aller kalengting services and Sing management options.	na Compaten Record	Mak kool wed	Becken Andysh	Devine andpak	Salama dinakan gilang dinasara kasing	Buck protogors we present that the second second dataset and the second second second second second second second we do the second seco		i hispolosiy	Male voluments, al least fil presail. Participant destings had been present allegeneral with real- stage preside concer-	8	Ne VCM/some(rs Red VCM/set auroup to inter VCM/set	Annual Lo VIA Annual Lo VIA Martin Ma
Polinan Strant 202	Polosa Arreat	del dellana. Arrent Mancon an	312 The Japan of Figlie E Valen Cardinatin Directors in a Prima Director of the Company of the Company Director of the Company of the Statistics Prima is Readonated Control of Teld		,	I Ir Chain In dan fire and you man (bi- bing) Band Band Band Band Band Band Band Band	son mor in spinor, for periods of the spinor of the spinor of the spinor (No. (No.	1 Gause parties	Differentiation and Convolutions (DBEC	Alter information provided at 2011 the discourt and testiment of	dent Computer-based	Makharofondi	Decision Analysis	Deckine and yets	kolycin of anthony allocing the material devices.	But outsing remains an exploit values during the status and always of a social test interparities of attributes information theory profile properties of attributes the protocols in the social distributes in the social forward in the interparities seening encoder and theory for the social social and the interparities meth- tic protocols in 1 but has and a of the binnership of the protocol in 1 but has	I	i kolgonitely	Newly disponent protocol priority priority with new priority priority with newly sing priority and Channess (4), vising disport Tay or (2), New 20, and Channess (4), vising decrementations, and faced with a transmissi decision.	16	DA (vel stavine) Ra informite/ve Di - ve VDB (vel stavine) est information + VDB (vel stavine) information + VDB (vel stavine) distribution + VDB (vel stavine) distr	denied mendled The mash vegges for by this 2 mer. () for tasks elifestion realistic and the sense of the sense of the sense () means for XII. The sense has a sense of the sense of the sense of the sense of the sense of the sense of the sense of the sense tasks of the sense of the sense has the sense of the sense of the sense the sense of the sense of the sense of the sense the sense of the sense of the sense of the sense the sense of the sense of the sense of the sense the sense of the sense of the sense of the sense of the sense the sense of the se
Panikt307	Pandel	landenkel (Fydenke	201 logoving klower (Freisen Midlag Jorfware with Kare Fan			2 5 Performance Information Information Information Information Information Information Information Information	lariha nataratu, () nanga 2, 3 nanga 2, 3 na	i Kerpis	Adaptine Danjske Andrijek (AD3)	Alter ar bhranchta scodan Iring súlt scinnarladis	on Companyhood	Mak keci sedd	Jalapor Gagas Junjo	ն <i>Անդու</i> ս-Շայնումանյա	 Perspect Research allows areas of advancements due to ad allows advancements that has proved a super- sentiation of the second advancement of the second accurate any sequence of the second accurate accurate any sequence of the second accurate	probabilities and set of the set		i kilyndoty	Adrine in Volenan Adrine Consortion Adrine Consortion Register and Adrine Markowski Register and Adrine Markowski Register and Adrine Markowski Adriane State and Adrine Markowski Pathola and Adrine Markowski Pathola and Adrine Markowski Pathola and Adrine Markowski	17 X ² residential of evoluted 3	i DA vs MDA Bar Bi de State VC Aus	Annual (1) of p () mutus popular (1) of the second of t
Provide 2008	Procide	Alexa Munderson Lo de	20 Inserv France Carlos Carlos Tegrando Kanakana Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Carlos Annorgi Ann	-		1 Thins	ne i o ba	i Gaure preside	No provide design per formation of the second secon	 Allen inhuman provid (dis de denor enforcement op enforcement op) 	dens Other	Sink hoot muld	The balant of ad shader only	ning Thurback of And I want of	uko (hara hara sakan saka ku	Chernol Statuses ingelvings matchicking association of the status of partner incomparison of the status of the status of the matrix of the status of the sta		4 käyndest	Man she has Wrone o schelikel der bei der sollte sollte sin Belde Aggestal Chais of Kine / Pennenne.	481	Countrol Ra v NCB and miniphong manufacture and ningkong manufacture and Rail v NSB and NSB	Abard Montal Source Pathylan exception 1000000000000000000000000000000000000
Gereeks 2000 († 1472)	. Groutsk	angoviddiffeerd	201 Viter-scheduren is a faiture of data trilly provide the scalar schedure product of schedure product of schedure product of schedure of schedure of schedure			1 2 Planers	mi ta dago manan a transmen	2 Reproduction local mode	B. No specific damp or interaction dented with a series	 Alexabered to solute del Alexabered to graphic metabolica Band solute patients 	nt Companishood is	Kong	Kong Kulo	Vical and g with	Remain the for all produced and appendix sectors and of the format oo th	and all ADM standard integrations and the standard integration and the		1 Mayadani	Rolly vour qui B. Stynould	111 Million angkite dat	VOR (0.5 mb) Rad almanna wajiwa ni tuku wajiwa ni almanna viXio 55 55	 entropiesto entropie

I	medl ()	Rxiv pr which	eprint doi: h was not cei	ttps://doi.org r tified by pe	/10.1101/2 er review)	021.01.2 is the au	1.21250 http://tune aunder a	270; th der, wi	his vers ho has	sion po grante	ed me	January 28 dRxiv a lic	5, 2021. cense to	The copyr display the	ight ho e prepr	lder for int in p	r this p erpetu	reprin ity.	t
Gererleis 2011 (1 of 2)	Gerrink	angershikifine d	20 The endershelp in the second and the second second and and and and any product of an analysis of the second second and any product of the second second and any product of the second second second and any product of the second second second and any product of the second second second second second and any product of the second second second second second and any product second second second second second second and any product second second second second second second any product second second second second second second second any product second seco		A the second secon	1 markin kuki ka		Grand Grand Control of	τα	Regisie.	Varlanig units	Para na logo program and program an	A set al set as a		nakody Badday war Si pana ati	ngal B. 199 Si'uni angka	VCR (AS walk as a statement of the statement as a statement of the statement administration with the schement of the statement of the statement of the with administration of the schement of the statement of the statement of the schement of the statement of the schement of the schement of the schement of the schement	Rech VCM-semantar of summers of the second s	spectrons 2 analyses for likeway as a CMA one and CCA or methods, and choose and choose and con- stantion of the con- tent of t
94ma 2001	ikes.	ladan (Reputeda	200 February Baston Torton Atomic Union Window Frances A Readward Chemistry Tort		 Washinov are to be mend for downsel. Washinov and the processing of the second se	1 Byyodiana Iraili. Adapt fami	vr ongelina sin om e DA 1967A)	Computer hand	Mah hund mult	Adapter Daján Andya	Adapter empire analysis	Parkipan Julian (kel parkinan semo sigi naman offang, semilansin se akadam, lagaray of ada aka see, panasawa, ad as	men schlass. Jesteins annur immediate Jesteins annur men schlassing men schlassing men schlassing men schlassing men schlassing men schlassing and queritiste schlassing der prefers men schlassing and men schlassing annur met schlassing a		vendoodly W verse signal datase with datase with the sense protocols of the sense were protocols and the event method is sense	Byone or 251 garden unselfalsen unselfalsen nor me	Sto USA (sometime) in USA (stopped a conjunc and part	netron in which day and like our of the measured Randomized constraints A field with 2 areas visites integri 11 constraints are using 11 constraints are using 11 constraints are presention which are analysis [2] small are constrained. A field are and a state and a state of the state areas of the state of the state of the state areas of the state of the state of the state areas of the state of the state of the state areas of the state of the state of the state areas of the state of the state of the state areas of the state of the state of the state of the state areas of the state of the state of the state of the state areas of the state of the state of the state of the state areas of the state of the state of the state of the state areas of the state of the state of the state of the state areas of the state of the stat	poletowar diskutan menkutow this ful met menkutow this ful met also diskika seguri o approre katamati diskataka. There is a nafi fur alakimad namikata ful met metalog aktional metalogi aktional metalogi metalogi aktional metalogi aktional metalogi metalogi aktional metalogi metalogi aktional metalogi aktional metalogi metalogi aktional metalogi metalog
Nyin 20	Next	kaad92e oo k	30 Selection (2016) Annual (2016) Contrast of Contrast of Contrast National Annual (2016) National Annual (2016) National (Particular to call and an and a second second and a second second second and a second second second second and seco	1 Conformation in Solger and	n engentaf Akor (MICI) - Akor (unted Online	Mak hood weki	Benina Andysh	Bankan andysh	Rating dang san biasi sengantan seng pada dari sebagai s	name for sensitive and branch and a find the sensitive and branch and a find the sensitive and branch and a find the sensitive and the sen		nalasiy Ganal dah popikan sa sonalah ki	X 38 wo	Då wik kolonanise promit for datals (* v promit for datals (* v mit er somet for data) mit er somet for data)	Reministration of an end of the second secon	her facility: a r-bh. minimized or consolided distances intervelop and transverse of the consolided distances intervelop and transverse of distances and the consolided distances and the cons
Barya 207	lkeys	andya karyati dako r da	30 Bios (columnation) Reads to be a sense from Production and a sense Production and a s		Participante de presente de la construcción de la construcción de l	 Mithodolis, Barrison Marcola, Barri	Alle shousts com (VCA)	Companyhood	Mah hund maki	Adaptor Gagine Andych	Adaptive compared and point	Mark approximation by the start approximation of the start start and start approximation of the start approximation of the start and start BDS.	And a second sec		nakandy Progle herang yana di aya anakan di aya ang kang di aya ang di	a (data) 20 baran Karan Karan Karan Karan Karan Karan Karan Karan Karan Karan Karan Karan	Tes hand Di wak da saman min yang sama ta kan nga sama nga sama ta kan nga sama sa sa sa mang sa sa sa sa sa sa mang sa sa sa sa sa sa sa sa sa sa mang sa sa mang sa sa mang sa	Read-mont of consolidat A index of the sector little of the sect	an intrastiva publicana and diministra und dar under publicana under ander publicana dara ander publicana dara international dara international dara international dara international dara ander dara anti-angenti ander dara anti-angenti antida dara antida dara antida dara anti-angenti antida dara antida dara antida dara anti-angenti antida dara antida dara antida dara anti- antida dara antida dara antida dara antida dara antida dara antida antida dara antida dara antida dara antida dara antida dara antida antida dara antida dara antida dara antida anti
Depulse-opps.2003	By selectope	per Window Spraws	20 Tomorphism appendix and appendix memory and the and appendix		 Anto-Instance Analog Anto-Instance Angel Anto-Instance Angel	1 Gaur panto Rom	ал ал а 10.	Companyhood	Mah hund maki	Adaptor Dagint Andych	Adaptive compared analysis	Advents of Barano, An or one supported.	properties and a feature in the large space of the properties of the large space of the properties of the large space of the space of the large sp	1 1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	nodmity Patients (1) at protocol and protocol and protocol and protocol and dependent of protocol and dependent of protocol and dependent depen	mail for 123 C (1) of the second seco	Transver vs MSB	Rankowski oranika Indexed James (1993), Pr Operation: Rankowski (1993), Pr Rankowski (1993),	he pulsas a unasond telbacilias deservatarias que real a datalitadas para esta datalitadas atál dataktara, melanda atál dataktara, melanda atál aposta datalitadas atál atalitadas atál atalitadas atál atalitadas atál atalitadas atál atalitadas atalitadat
Krunniy 202	Kennedy	andere leannely Women Lanak	2012 Hillen of Distance Adv. for Meanshipping in Transmer Charm, Halth Discound Charm, and Char. A Resolution of Discould Chard	, ,	4.0 mm ² Online for mean dispate (solution and meansion) (solution and meansion) meansion of meansion of the solution in the solution of the solution of the meansion of the solution of the solution of endowed dispate the solution of the solution of endowed dispate the solution of the solution of the solution of endowed dispate the solution of t	1 Beyeshnine beakh. No spo insule somenhagin insure anale	elle danny w Aldre telemation (SA has of annexissed in and takes)	slalar. Yinbad jonn sonal isomiring sish paper (busklit messagar wanter is sonal data pathement)	Lia of ensens (sorvire)	lår of Concess	Disease only	Barrand Mercines help pains, shelp out a polymetry and a polymetry and possible additional information.	the process or work of control channels with the second second second second replicitly the second second second second with the second second second second second second second second second second second protocol second seco	а тим	amanda menar Wanny shida menangkana menantagia	24	Standard practice (unstainly vs NCM (inversion 2) voluto-basedine NCM (udate-basedine)	Reministeried with Tarens. Yet To a standard province on control gauge with sum Per- temportal standard provinces of information groups with a di- terior standard standard standard standard excitation groups with a di- standard standard standard standard standard standard standard standard standard standard standard standard standard standard standard standard standard	influe intervention had a effect on builds takes, inviding women with dimension alow of dimen- flue invidence deniers; a historier to chaify does and shift effects of the influence effect on marks mangement and rasked is enhanced entit.
Engreen Mi	Kepresen	lagamandi daga unink	362 West Advanced Advances Values Description of the Order Advances Manual the Order Advances Theory News, A Machine of Marcel Tel West, A Marcel T		Neural Neurophysical Control (Neurophysical Control (Neurophysica	1 Result converge	da dang ut	penul Companisati Inning	lang	Kong Kulo	tiler units	The case is the scalar is sequely a value , shows in the problem of the scalar is the scalar is the scalar problem of the scalar is the scalar is the scalar is the scalar is the scalar is the scalar is the scalar is scalar is applied in the scalar is the scalar is the scalar isophysical in the scalar is the scalar isophysical interaction of the scalar isophysical interaction of the scalar scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar isophysical interaction of the scalar	starspurste sta		natarah Ragisha or Japan yanking mu yanking mu patrian kugi patrian yang patrian yang mu ang patrian yang mu ang patrian yang natarah yang patrian satarah y	anah. 120 man An Andrea An Angle An Angle	Information and a second synChild - Mathematica Information on Auto- matical Association and Association synchronization and Association synchronization and Association synchronization and Association and Association and Association and A	normalization. Head and the second s	Winglementation of remain testing a statistics, using a supported of the statistical and the statistical statistic
Longa 1997	low	a a tree mail de mar de mar de	Int Country Society and Soc		2 Shakaragan ya hutu kukaragan kukara kukaragan kukaragan kukaragan kukara kukara kukaragan kukaragan k	1 Gaun James	new make and the second	a Yuhdina dawira munda jang ya ung ad munda jang ya ung ad munda jang ya ung ya ya ya ya ya ya ya ya ya ya ung ya ya ya ya y	Eat of annuma local.	Las alumanes	Dames of	Also for device of the problem on the problem of the temperature of the second se	and a set of the first sector of the sector	. 2 4 60 	anara ang ang ang ang ang ang ang ang ang an	20 Jone (D. Donald Martine State 20 Jone (D. Sta	inter Destruction (Construction) enter Destruction enter (Construction) EUT - (DA	Researcher 2 (se many Arrowski) rady, 7 (se manufacture) rady, 7 (se manufacture) rady, 8 (se	a profilioral, company distributions of the second properties between the second second second second second second second second second second second second second second second second secon
Madam Kesk 1997	Meleo Xali		(40) Indiana of a spins discovering on originate horizon differ source of the spin of the spin of the spin distribution.		Neurons Politeness Recard to Annual care of Robinsol transports	 Advancel corplining. These dominantleography declaration of the second se	of sample and and a DA	Tabul	Liat of concerns (interview)	lår of Concess	Raing and int and shown	Printinetine Poly you van Yohna, bei you yi a	al diverse . Ruch wome was schol in indicator from direct from diverse indicator from each indicator from each indicator in the multi- distribution in the multi- distribution of the scholar scholar between pumption of all the scholar between pumption of all the scholar between indicators are all senses and distributions and scholar between indicators and scholar between the scholar between and scholar scholar scholar between in the scholar scholar between distribution and scholar between The much scholar between the scholar between the scholar between scholar between the scholar between the scholar between the scholar between the scholar between the scholar between the scholar between the scholar between scholar between the scholar between the scholar between the scholar between the scholar betw	4 3 Wa daa	lidy sampar Noora con- tinandar berlag a box madar and particle program	ge 70 and 60 cone facily of side of a set	Sin WSM (and downskin) vs WSM (downskin with a paray)	Emiliarized Quantum d Raminosited Quantum d and proy independents pro- mal energy independents pro- solution values d without values d independent programmer d without values d independent programmer d independent pro	Clif of the constraints could be constraints or equivalent in increased merginese of the last and metricisms of 2004 REA1 resing, but knowledge on an better than docution adore. The instruction generated the instruction generated the instruction generated the instruction generated and instruction generated and lines inflavored merginisms, of the orders of REA1 resign devices on
Mongowy 200	Maspary	dan a mangunang Pint undan d	20 Alexandrom and a second a		 Newswork and Approximate Approximate 	1 Onlowershipmen, VOM Spannens, Anna Spannens, Spa	nghi ha ha Barang ya shi ka ka mana k	n Compatin Navadi o carate inin	Mak husul meki	Bosinan Andysis	Donkins andpole	Answer within some answer of a bing a sumption to the second second second second second second second balance of the second second second second second second second second sec	Variante de la construcción d	1 1 <u>90</u>	Top dak anta-anta-anta- anta-anta-anta-anta- nanta-anta-	Sillyon 27 panol	No VEM (sound over constrainty to VEM or analysis to solve a solve the solve of the solve and the solve of the solve of the solve and the solve of the solve of the solve and the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of the solve of	Rambound 2x,2 hoursaft 7 datage. Research waves for adapts. Provide states of the analysis of the data states of the analysis of the data states of the analysis of the data states of the Research of the data states of the data states of the Research of the data states of the data states of the Research of the data states of the data states of the data states of the Research of the data states of the data states of the data states of the Research of the data states of the	The study has concernited that both senses that the sense has been been been been been inder the sense been been been inder the sense been been been inder the sense been been the sense been the sense the sense been the sense been the sense the sense been the sense the sense been the sense the sense been the sense the sense been the sense the sense the sense been the sense the sense the sense been the sense t
Musepoory 2027	Margurery	dia sampany Vie	387 Technon feb telanat Construction feb telanat Construction feb telanation Construction feb telanation Construction		 One of plane shares and a second secon	1 Rayadowine manual Udity i kulik manu of deleny	Alex Montenia Alexa da Series de Series de Series Series de Series de Series de Series de Series Series de Series de Series de Series de Series Series de Series de Series de Series de Series de Series de Series Series de Series de Se	y Jenual ngang	Mak hundrandi	Ensine Andysh	Bashin miljak	Were not give a dispersion of our of the state of the sta	Additional and a second additional		ntinal-scalara mand-scalara program trains. Inte mand the scalar manual scalar equation of the scalara scalar scalar scalar equation of the scalara scalar scalar scalar equation of the scalar scalar scalar scalar scalar equation of the scalar scalar scalar equation of the scalar scalar scalar scalar equation of the scalar scalar scalar scalar scalar scalar scalar equation of the scalar	ng 12 Be valkanse Sakang Sakang Yanak	No HSM (person and person MSM (phases and person to kilometer and p	Rendominad annumber () indexek annu 1990 (alcohan an departy) (alcohan an departy) (alcohan an departy) (alcohan and annu (alcohan annu)) (alcohan annu) (alcohan annu (alcohan annu)) (Interpret to could do taken the sense matter regularization of smaller segments counter, with some counters with the sense of the sense of the sense that is even with the sense that is even with the sense of the sense of the sense matter of the sense matter of the sense that is a sense of the sense of the sense that is a sense of the sense of the sense of the sense that is a sense of the sense of the sense of the sense that is a sense of the
Nyee 201	Mpon.	ana gara Basti ganh	Mar Yanan Antonio Mariana Marao Katana Mariana		2 Whiteson to be a set of the set	1 Own years Andy	salihali Peres Akeriki Johannini	Yoshafashigaqan Goodda entrend akk Rakkeduster	Math hereof work of	Andyin (Throughy Proces	AndyrickBarrenby	The back is a low program for points on the other than the program is a strain of an algorithm of the program is a strain of the	 basarangan basarangan basarang basa	1 1900 100	animan kana kabuar kabu	stiftshar 19 h dalman Par Par Par Par Par Par Par Par Par Par Par	No WAR (DA well) i w WAR (Da v Antoine controlling second)	Rankowski anovili i i indexid anovili i i indexid anovili i i propriori i i propriori i i i propriori i i i i propriori i i i i i propriori i i i i i propriori i i i i propriori i i i i propriori i i i propriori i i i propriori i i i propriori i propriori propriori propriori propriori propriori propriori proprior	he VSM proughed remains and extension in the standard international group fields. Comparison of the standard standard standard standard standard constraints and standard constraints and standard constraints and standard

r	nedl ۱ <mark>)</mark>	Rxiv pro which	eprint doi: hi was not cer	ttps://doi.org/ tified by pe	/10.1101/2 er review) It is made	2021.01 is the availa	1.21.21250 author/fun able under	<mark>270</mark> ; t der, w a <mark>CC</mark> -	his ver ho ha: <mark>BY-NC</mark>	sion p grant C-ND 4	osted ed me .0 Inte	January 25, 2 dRxiv a licer	2021. The use to disp ense .	e copyrigh play the p	t holde reprint	er for this in perpet	preprint uity.
Mper 200	Mpros.	nagatifukipak	300 Taylord, Silkon Lancash Mar Al San Kang San Kang San Kang San Kang S		 Means one is the same of processing sources of processing of the processing sources of processing of the processing opening and processing of the processing opening and the processing of the processing opening and the processing opening of the sources opening opening of the processing opening ope	1 Geor peste	Ny ny kaodim-paositra 2014 amin'ny kaodina 2014 amin'ny kaodina 2014 amin'ny kaodim-paositra 2014 amin'	iam Understüngene Beställer ander Indelik oftenstellt	Mink how/mink	Andpited Horneby Process	. Andynaithinnely	Design of the second se	h akine so manning the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source of the source	1 I Yakan dan kata kata kata kata kata kata kata ka	Allen Allen Andreise mer Januar bereinen Ster Bertraufen und einen Allen Bertraufen und einen Beitrege Organisation wannen	22 No Will standing intervention of the standard standa	Manual et al. 2015 Statistical et al. 2016 Statistical et al. 2016 Statistical. 2016 Statistical. 2016 Statistical et al. 2016
GCourse 2000	00mm		10 Technologi vajet valet desentransen entransentransen entransentransentransentransentransentransentra entransentransentransentransentransentra entransentr enteransentransentransentransentransentransentransentransentransentransentransentransentransentransentransentran enteransentransentransentransentransentransentransentransentransentransentransentransentransentransentransentra enteransentransentransentransentransentransentransentransentransentransentransentransentransentransentransentran enteransentransentransentransentransentransentransentransentransentransentransentransentransentransentransentran enteransentransentransentransentransentransentransentransentransentransentransentransentransentransentransentra enteransentransentransentransentransentransentransentransentransentransentransentransentransentran		3 Webserver work Restance optimised Analy delensinger	 Republication leaders. Read-anneques- in-state complexitient and an experimente 	Under Space formy Marchardson (Index) and Antonio Marchardson (Index) in Antonio Marchardson (Index) Antonio Marchardson (Index)	n and Piper DA also has hengy andhengu)	Proceeding	Pen and Gan	Walt-regiling	The straight of the straight	and provide a solution of the	, termene	Wanna qui Abili quat, mergene di statuta denge, merce denge,	20 Noveehan VM n Region VM	Antopos um subantar acuantar
Pagan 255	Papain	guyakiling	343 Astronomics and an experimental and astronomics and general synthesis and general synthesynthesis and g	1 2	 Whether an issue property space and ended on property shares in and day. 	2 Resultaney	Romand with Adve Manager (2014) Adve Manager (hen Galer	Pan and care	Pen and Gans	Wahinay	Vice industry and the day laws of the expension of the second balance of the second balance of the second second balance of the second balance of the second second balance of the second balance of the second second balance of the second balance of the second balance of the second balance of the second balance of the second second balance of the secon	 Alers reading and a second seco	2 3 kingudang	Weaten and one opp 14. If the two program was seen on the second second second second second program of spinore are spinore as the heaten program is the second program is the second program is the	MB Distanty or with a	25 Manuari University Description (1997) And Anton Manuari
Penals 209	Prinzle	and the second second	28 Westerne and Annual Manual Datase Barlay Manual Datase Supervised Sector Sector Sect		2 Tababa sa tang pana nggapa ang anggapa ang anggapa ang anggapa ang ang ang ang ang ang ang ang ang an	2 Seden county	Bana binama	Galax	Pro. and -ress	Pen ad Cas	Xikhhay	A shad when the research with plane to a first sector of a shad the sect	 Total and the second of the sec		We want with the many set of the	80 Dianjo di vi	CS setup: set
Pigener 202 (1 of 2)	Param	pigeneil nel an eis	2011 Ouppin Andyn Wenn Keing and Barling do Yuhon Bhitsin and Charling the Outpin Ochimic Court Barling		8 Whethere are in the summed for educated control (4) (yes, what control(4) (yes) and (yes) designed to similar field designed to similar field d	2 George and and	Յողմուսակոն ու ու ենձ	Computer hand	Math Investmented	Durste Christ Equipment	Diserve desige reprises	Diserter desire tooli Per endvach, der perkenpert was anheid eksenselwennen optima 1 and 2 ar some des dieg half an performant betrann die van.	supporting law in Couples table black hears task investiged law supporting ($\gamma^{*} = ad (\gamma^{*})$ such as gradient ($\gamma^{*} = ad (\gamma^{*})$ such as gradient such as the support of the support such as the support of the support become spectrum. I as a partners becomes the new.	i é helynatosty	Adults, B. Yan aronge shild be obtain a summer (so provide the state of the state provide the state of the state provide the state of the state summer, projects of sharmonic playmer sharmonic playmer	16 M(s/a staling 200) waleful (interest vs. USA with replace staling) (interest staling) (interest staling) (interest staling) (interest staling)	Rachanised. (Conjone Different types of VEH heavy). Restore datase VEH 3. In the of indifference patterns of the second data of
Pigener and (cm.c)	-rijuan	hima an re se	anni an Annaichte Annaichte ann an Annaichte Christeanna Christeanna Christeanna Rennaic		 It transmit for noticerail control of a set of the set of the second part of the set of the second part of the set of the designation of setting designation of setting designation of the set of the set of the set of the set of the making and set of the CT and set of the set of the set and set of the set of the set of the setting and set of the CT 	A LANCE AND DESCRIPTION	Per Special candida and a second and a second and a second and an anti-	- Alexandrian (1997)		radiustrati	kong an inang	nang san an remanin mang	Some given its status quite. The using sevents and add participants to status, on a likeness status of 1.6. Address importants of finals desibute (1) and a legislation (2) status importants. (The random gate is and due force maximplication and due force maximplication of the visc antiduces.	. and here a	Addit 40.152 arms(n presenter innerfate fang) history di admi range, polyty or infamminy hered afannes/	Jia Wata Kanani Sawata Jiao 200 malaka kilometer va MM withouter nakelih jiao ya kung an andang ji mila kilometer	Mathy Jianwa Antion VIEI, Si Jian Jiang and antiong VIEI. So the 1 of 2019 and to you and the Kening and antiong VIEI. Insidence on guestion and the second seco
Piguese 2013 (2 of 2)	Research	Misher(Pipear/Feel mode	2013 Computing there to during an Arr relating guinest values for drokalam making and any provider specific angingen somewing: a machinesis of controlled total	i i	2 Wholes or not infor sevenced for provision cancers.	3 Gauss-passide	No specific theory set Insurance mentioned in EA3 about product com- ations PEAs secondary	ne Fit) a Collar er end	Printigeire ennise	Rates and Rosting	Roing and ranking	Kaing and undarg Tech	Raving and Raving Tash. The statig and saving tash added participative in mite jum a scalar flow into important at all to 1 v row jumportant jump then and the share next important scenario participation autobarts. Immority tables key simburs.	l á knigendenty	Accord pretick(), a with an presentator family history of product cannot sum aged 10.55 (seculars of an unline carry panel).	911 Madinatod VCM wikreplek (SE-coupleted maked), silonere rawning vs. VCM without re- mained), tring an anality or VCM without re- mained), tring an anality or VCM without re- implies replace and (balance short)	Rankrained 2(inplicit Different values bacie) VDA (histoner elsers of elsefaciarian methods) delta fary size industry (VDA), else affastera journeau i meig and analog VDA, else affastera journeau i (discute closie) volta and discute professore reportienes). presented with an architectul else.
Piguese 2013 (1 of 1)	Parent	Malat Jpost/Fed.	301 Organization of the second sec		 The holes on the second for proceed and the second for proceed and the second for proceeding and the second second	3 George parate	No coperation of the second se	mr PFr. + Online and	Mitch boostenside	Burste Christ Barstone	Disorte deste reprisest	Channel Address and Market	Bits of the second seco	1 i hingandaniy	A comparable of with our program of the second second second second second second second second second second second second second second second seco	(1) Erdanud (Ulicapito) (Ricapito) antiki/ antiki/ selection an	La constanti a la constanti a
Hender 200	lexis	3.000 gadaan ah	MR Hourse Annual A Annual Annual Annu	. ,	1 Particular un et a martin andre la van de la van de la van de la van de la van de van de la van de la van de van de la van de la van de van de van de la van de van de van de van d	2 Gudern ske dran og var fan dran GBB	 Topped land a state of the spectra design of the spec	ter üder	Pikelingsber eine ker	Kating of edg	Koning ad oring	Kanta an anna an sun a stà an d'An Anna. In Francesco - Anna a sha sha anna an Anna anna anna anna anna anna	Reading and interpretation of the section of the se	1 I holyandardiy	Man Joguny professional and B. B. And San	17 Bitaniyan Bita A	20 Lange 1995. And a sense of the sense o
lina 307	ini	jakit Forderaukosk	20 Research & Reproductions in the Association of Control of Control Control of Control of Control Research and Control of Control Research and Control of Control Research and Control of Control of Control of Control Research and Control of Control of Control of Control of Control Research and Control of Control of Control of Control of Control Research and Control of Con		 Chan between their field proton stars and proton stars and analyzes of the stars and and analyzes of the stars and and analyzes of the stars and analyzes of the stars and and analyzes of the stars and and analyzes of the stars and analyzes of the stars and and analyzes of the stars and and and analyzes of the stars and and and and and and and and and and	i Gaure poside	Oran faith any en- try of the second	darra Carpin hod	Mith kentuchi	Bas Rose Koleg	Recovered	Banin dala gglania	anter opision internet Respective and internet anter opision in the interpretation of th	1 Enterandor y pro- province physical	is Max with mailow Reduct protot course at The Angelon dates.	12 Pedro trajente 1 - Sector Pengeno 1 - Sector Pen	a) Sharpen Linux J. Managan Linux J.
Vienna 202	Vienas	kilj stimet Hada	20 Editoryangen Univ Characteristics Network		3 Maken one taken skankding seasant spans taken.	i kanada dha	 Noncole Status - J. Alexistanti and Alexistanti and	an Caspanhaol	Sinds been from het	Bashim Andph	Berkhersondych	Perspectra con classica in dedare for property of comprehension of comprehension of the second	10 Binking Manual Andreas Manual Andreas Andreas Andreas Manual Andreas Andreas Manual Andreas Andreas Manual Andreas Manua	1 I bayantan	Pennin quel la span ulas male mini- dicidante fora listerior discidante fora listerior yones and desarrollar la forar y en manufacilité de venante	11 Opplearum; - Aff Edings - Samarin Kang - Samarin Kang - Samarin Kang - Samarin - Sa	 Handback Handback<
Waterne 200 Ja	Virmer	kely winese if hed al	2010 What helps people order values, response method densities Tilleren skningtes treined averes sin studies		2 Berrankomperie	2 Gauss ofin	No spoille dansy ar innernia menianal in gyna d'angrej ta mar attala	und Galar olar	Math Investmented	Decision Andysis	Decision andysis	Benegy (a total visual leave replosily indensity participant althe first if foreigns	a Strategy 2a District shand finance registed paintening participants of the both IB for them. Birth visual Fatasane then algored within the strategy of the parameters of the strategy of the parameters of the strategy of the strategy parameters of the strategy of the strategy of the strategy of the strategy of the strategy of the strategy of the strategy many visited on the strategy.	2 i holgendosty	Adults aged 18 process older bring in the Usual Source of the Source Party of the Source party optimized in the Biglish Inspirate other survey.	 Zi'le constit No VCM vs VCM) group and Zi'le v shoul with informat VCM group about here about 	American and Sec. American and American Americ
Witema 200- 2+ 26	Viene	holy witeward Windol exdex	200 Bock by party and roken. represent address to the set sample standards to chain a		2 Bernenhampende	2 Gaurendes	No appella desegui a March Managana andra Bananda desenina de la genera d'argun y tenna andre	oni Online este	Mak hund melel	Bashim Andysis	Decision analysis	Hence g_{i} is a single star shell have been by the single set of the single star shell have been been as the single set of the singles	 Bourge grade by a finite stand Bourse specifies by the bourse Bourse specifies and the Bourse specifie	2 I fudquadouty	Adalis agod El youn or older bring in der Unied Hann an all der Belle participate ein an Beglehe Ingesogranden sonrop.	(20) 2716 control 20, 500 400 - 500 (year gain of the second	(ad) Enablished in construction in wWW Systems to the construction of the set of the
Viewe 200 - 8	¥2mms	kaly strong Hard at	30 The head of the second s		2 Bernendening und	2 Gaurados	No particular de la conservación	en2 Odier	Process	Pen and Gan	Lang	tere di norma di scherichi di s	Manufactoria in terretaria dari dari menungkan terretari dari menungkan terretari dari menungkan terretari dari menungkan terretari dari menungkan terretari dari dari menungkan terretari dari dari dari dari dari dari dari dari dari dari dari dari dari dari dari	. 3 Kanpadanij	Adden angel Stynes or an effective state of the state of the state form and these provingers on an Equity is being any other merely.	10 Giro and State and S	Markaning and an angle and angle an

medRxiv preprint doi: https://doi.org/10.1101/2021.01.21.21250270; this version posted January 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 30 422 in control and 301 presentational dynamic with 51km preparing a statusty fa-restring statusty fa-restring and statusty of prestrygativelases, challenin statusti d matig attelears) 2 Gauss unless No specific theory or Alter information insurence mentioned in types of corpore article. Stating 1 web shield Bentegy Br. Dynamic web chiles where the individit is the decision wave made replicit (where the participue mered are thirt extension sigh the other chiles extension and the other chiles automatical mered dor experiences 827 d22 in control No VCM vs VCM Readinated to storeborn and 2019 (controllated dynamic intervention or dynamic metrics) with class shares with class where day unatogy the maleofile is dor dynamic ware made realist? were made realist. 2 Here Montegy for Dynamic work videos replicitéj indirensing participants of the hore its in these jobses the participant mercul and schlar there, quarters ari due way to the right for anomalised restrict her second automatically there quarters, of the way upi. No specific domay or Allow information socions on 2 fone-work meeting in types of suppoy to tensi color anticle. Stategy is web shider Adults aged 18 years or older loving in the United Nature and able to participate in an English-language onder survey. 842 dDiscontrol No.VCM or VCM Monitoria of the section and 240 (seconstrained dynamic inversion) with thins: resplicit unstring the implementary unstring for implementary of the second sec A partectplind writing schere cheffication method (Rentryy In) allered an Israellin israe of taken component compared the control condition, dal weath in releved decision condition. Compared to Biostopy 2020 What helps people under values. compared method doctors with the set character second across size studies Numergies the and do together (i.e. constrained dynamic web vibles and accounted participant survers are a billion web of bill by more used the enter table and strength by one write and the accounted owned than, more up and exercise the accounted owned than survey or and accounted owned by the strength of the strength by one with and the accounted owned than survey or and accounted owned by the strength of the No specific theory or Allow information societors on 2 insurance specificant in types of suppoy to transicular article. Surregies the de-Adults aged 18 years or older lockg in the United States and able to participate in an Degleh-language online survey. 333. 422 in second. No VCM vs. VCM. Readonized is necessarily and 423. (constrained systemic intervention or VCM receiving with shifts and constrained systemic vs. (constrained dynamic unstrained in the systemic system) with shifts and the receiving version by second systems. A printippiad 'using values clatification method (Rentry) fail allowed an browth in terms of values comparement compares the availed condition dal works in reduced

Online Appendix 3. Additional Results

Additional Meta-analytic Results

Figure S1. Values Congruence by Tradeoffs

	VCN	1	no VO	M		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.2.1 Explicit tradeoffs								
Sheridan 2010	3	62	6	75	5.9%	-0.03 [-0.11, 0.05]	2010	
Jayadevappa 2015	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	+
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	
Witteman 2020 6b	68	395	93	422	10.9%	-0.05 [-0.10, 0.01]	2020	
Witteman 2020 2a	43	239	59	217	6.5%	-0.09 [-0.17, -0.02]	2020	1
Witteman 2020 2a + 2b	26	237	41	217	8.4%	-0.08 [-0.14, -0.01]	2020	
Witteman 2020 6b + 6c Subtotal (95% Cl)	59	413 1894	93	422 1905	11.6% 66.5 %	-0.08 [-0.13, -0.03] - 0.05 [-0.08, -0.02]	2020	•
Total events	311		423					
Heterogeneity: Tau ² = 0.0	0: Chi ² = 1	10.41.0	df = 6 (P =	= 0.11);	$ ^{2} = 42\%$			
Test for overall effect: Z =	3.49 (P =	0.0005	5)					
2.2.2 Not at all								
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	
Witteman 2020 4b	74	350	93	422	9.9%	-0.01 [-0.07, 0.05]	2020	-
Witteman 2020 6a	85	363	93	422	9.8%	0.01 [-0.05, 0.07]	2020	+
Witteman 2020 6c	79	440	93	422	11.2%	-0.04 [-0.09, 0.01]	2020	
Subtotal (95% CI)		1254		1366	33.5%	-0.01 [-0.04, 0.02]		•
Total events	273		312					
Heterogeneity: Tau ² = 0.0	0; Chi ^z = 3	2.06, df	= 3 (P =	0.56); P	² =0%			
Test for overall effect: Z =	0.75 (P =	0.45)						
Total (95% CI)		3148		3271	100.0%	-0.04 [-0.06, -0.02]		•
Total events	584		735					
Heterogeneity: Tau ² = 0.0	0: Chi ² = 1	13.88. (df = 10 (P	= 0.18); I ² = 289	6	E.	
Test for overall effect: Z =	3.42 (P =	0.0008	i)		2		-1	-0.5 U 0.5 1
Test for subaroup differer	nces: Chi ^a	= 3.47	df = 1 (F	P = 0.08	6), ² = 71.	2%		Favours vom Favours no vom

Figure S2. Values Congruence by Implementation/Presentation of Results

	VCN	1	no V(M		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.2.1 Presentation of res	sults							
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	
Jayadevappa 2015	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	+
Witteman 2020 6b + 6c	59	413	93	422	11.6%	-0.08 [-0.13, -0.03]	2020	-+-
Witteman 2020 6c	79	440	93	422	11.2%	-0.04 [-0.09, 0.01]	2020	
Witteman 2020 2a	43	239	59	217	6.5%	-0.09 [-0.17, -0.02]	2020	10
Witteman 2020 2a + 2b Subtotal (95% CI)	26	237 1877	41	217 1830	8.4% 60.8%	-0.08 [-0.14, -0.01] - 0.06 [-0.09, -0.02]	2020	•
Total events	319		417					
Heterogeneity: Tau ² = 0.0	00: Chi ² = 1	10.07.	df = 5 (P =	= 0.07);	$ ^{2} = 50\%$			
Test for overall effect: Z =	3.25 (P =	0.001)						
2.2.2 No presentation of	results							
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	2
Sheridan 2010	3	62	6	75	5.9%	-0.03 [-0.11, 0.05]	2010	2
Witteman 2020 4b	74	350	93	422	9.9%	-0.01 [-0.07, 0.05]	2020	+
Witteman 2020 6a	85	363	93	422	9.8%	0.01 [-0.05, 0.07]	2020	+
Witteman 2020 6b	68	395	93	422	10.9%	-0.05 [-0.10, 0.01]	2020	L
Subtotal (95% CI)		1271		1441	39.2%	-0.02 [-0.05, 0.01]		•
Total events	265		318					
Heterogeneity: Tau ² = 0.0	00; Chi ^z = 3	2.81, dt	= 4 (P =	0.59);1	²=0%			
Test for overall effect: Z =	1.10 (P =	0.27)						
Total (95% CI)		3148		3271	100.0%	-0.04 [-0.06, -0.02]		*
Total events	584		735					
Heterogeneity: Tau ² = 0.0	00; Chi ² = 1	13.88,	df = 10 (P	9 = 0.18); I ^z = 289	6		
Test for overall effect: Z =	3.42 (P =	0.0008	i) `					-1 -0.5 U 0.5 1
Test for subaroup differe	nces: Chi ^a	2 = 2.92	df = 1 (F	P = 0.09	B), ² = 65.	7%		FAVOUIS VOM FAVOUIS NO VOM

Figure S3. Values Congruence by Stated Use of a Theory/Framework

	VCN	1	no V(M		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.2.1 Stated theory								
Jayadevappa 2015 Subtotal (95% CI)	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	±
Total evente	17	343	21	550	10.7 /0	-0.01[-0.04, 0.02]		• ¹ 2
Hotorogonoity: Not applic	ahla		21					
Test for overall effect: 7 =	0.60 (P =	0.55)						
	0.00 (1 -	0.00)						
2.2.2 No stated theory								
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	10
Sheridan 2010	3	62	6	75	5.9%	-0.03 [-0.11, 0.05]	2010	
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	2
Witteman 2020 2a	43	239	59	217	6.5%	-0.09 [-0.17, -0.02]	2020	1
Witteman 2020 2a + 2b	26	237	41	217	8.4%	-0.08 [-0.14, -0.01]	2020	
Witteman 2020 4b	74	350	93	422	9.9%	-0.01 [-0.07, 0.05]	2020	-
Witteman 2020 6a	85	363	93	422	9.8%	0.01 [-0.05, 0.07]	2020	+
Witteman 2020 6b	68	395	93	422	10.9%	-0.05 [-0.10, 0.01]	2020	
Witteman 2020 6b + 6c	59	413	93	422	11.6%	-0.08 [-0.13, -0.03]	2020	-
Witteman 2020 6c	79	440	93	422	11.2%	-0.04 [-0.09, 0.01]	2020	
Subtotal (95% CI)		2805		2921	81.3%	-0.04 [-0.07, -0.02]		•
Total events	567		714					
Heterogeneity: Tau ² = 0.0	10; Chi ² = 1	10.83, 0	lf = 9 (P =	= 0.29);	I ² = 17%			
Test for overall effect: Z =	3.79 (P =	0.0002	:)					
Total (95% CI)		3148		3271	100.0%	-0.04 [-0.06, -0.02]		•
Total events	584		735					
Heterogeneity: Tau ² = 0.0	0; Chi ² = 1	13.88, 0	df = 10 (P	= 0.18); I ^z = 28%			
Test for overall effect: Z =	3.42 (P =	0.0008	6		2			-1 -0.5 0 0.5 1
Test for subgroup differe	nces: Chi ^a	= 2.64	df = 1 (F	P = 0.10)), ² = 62.	1%		Favours vom Favours no vom

Figure S4. Values Congruence by Real/Hypothetical Decision

	VCN	1	no V(M		Risk Difference		Risk Difference
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
2.2.1 Real decision								
O'Connor 1999	35	101	33	100	2.6%	0.02 [-0.11, 0.15]	1999	1
Jayadevappa 2015	17	343	21	350	18.7%	-0.01 [-0.04, 0.02]	2015	+
Witteman 2015	95	205	110	202	4.4%	-0.08 [-0.18, 0.02]	2015	
Subtotal (95% CI)		649		652	25.7%	-0.02 [-0.07, 0.03]		+
Total events	147		164					
Heterogeneity: Tau ² = 0.0	0; Chi ² = 3	2.67, di	= 2 (P =	0.26); P	²= 25%			
Test for overall effect: Z =	0.86 (P =	0.39)						
222 Hypothetical decisi	on							
Shoridan 2010	ол Э	62	6	75	5.0%	-0.02 [.0.11, 0.05]	2010	
Witteman 2010	74	350	93	122	0.0%	-0.03 [-0.11, 0.05]	2010	+
Witteman 2020 45	85	363	03	422	0,9%	0.01 [0.05 0.07]	2020	
Witteman 2020 6a	68	395	93	422	10.9%	-0.05 [-0.00, 0.07]	2020	· · · · · · · · · · · · · · · · · · ·
Witteman 2020 66 + 6c	59	413	93	422	11.6%	-0.08 (-0.13 -0.03)	2020	
Witteman 2020 6c	79	440	93	422	11.2%		2020	
Witteman 2020 2a	43	239	59	217	6.5%	-0.091-0.17 -0.021	2020	
Witteman 2020 2a + 2b	26	237	41	217	84%	-0.08[-0.14]-0.01]	2020	
Subtotal (95% CI)		2499		2619	74.3%	-0.04 [-0.07, -0.02]		•
Total events	437		571					
Heterogeneity: Tau ² = 0.0	0; Chi ² = !	9.45, di	= 7 (P =	0.22); P	²= 26%			
Test for overall effect: Z =	3.47 (P =	0.0005	i)					
Total (95% CI)		3148		3271	100.0%	-0.04 [-0.06, -0.02]		•
Total events	584		735					
Heterogeneity: Tau ² = 0.0	0: Chi ² = 1	13.88.	df = 10 (P	= 0.18); I ^z = 28%	5		l e de le d
Test for overall effect: Z =	3.42 (P =	0.0008	i)			-		-1 -0.5 0 0.5 1
Test for subgroup differer	nces: Chi ^a	² = 0.68	, df = 1 (F	^o = 0.41), I ^z = 0%			Favours VCM Favours no VCM

Figure S5. Decisional Conflict by Tradeoffs

		VCM		n	o VCM			Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.1.1 Explicit tradeoffs										
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003	
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	8.0%	-0.28 [-0.48, -0.09]	2007	
Frosh 2008	27.95	13.45	153	30	10.77	151	7.1%	-0.17 [-0.39, 0.06]	2008	
Kuppermann 2014	12.9	14.1	357	13.8	15.6	353	9.7%	-0.06 [-0.21, 0.09]	2014	
Garvelink 2014	41.6	9.5	66	44.1	12.3	66	4.4%	-0.23 [-0.57, 0.12]	2014	
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017	
Hopkin 2019	14.59	15.04	122	23.13	20.34	136	6.5%	-0.47 [-0.72, -0.22]	2019	
/Vitteman 2020 6b + 6c	36	27	413	42	27	422	10.1%	-0.22 [-0.36, -0.09]	2020	
/Vitteman 2020 6b	39	27	395	42	27	422	10.0%	-0.11 [-0.25, 0.03]	2020	
/Vitteman 2020 4b	35	28	350	42	27	422	9.9%	-0.25 [-0.40, -0.11]	2020	
Subtotal (95% CI)			2213			2348	75.7%	-0.22 [-0.34, -0.10]		•
Test for overall effect: Z= 1.1.2 Not at all	3.67 (P	= 0.000	2)		100					
Epstein 2018	9.09	2.35	61	9.48	2.23	61	4.2%	-0.17 [-0.52, 0.19]	2018	
Vitteman 2020 6c	36	26	440	42	27	422	10.2%	-0.23 [-0.36, -0.09]	2020	
/Vitteman 2020 6a	35	27	363	42	27	422	9.9%	-0.26 [-0.40, -0.12]	2020	
Subtotal (95% CI)			864			905	24.3%	-0.24 [-0.33, -0.14]		•
Heterogeneity: Tau ² = 0.0	00; Chi ^z =	0.26, c	f = 2 (F	e = 0.88)	; I ² = 09	6				
Test for overall effect: Z =	4.95 (P	< 0.000	01)							
Total (95% CI)			3077			3253	100.0%	-0.22 [-0.31, -0.13]		•
Heterogeneity: Tau ² = 0.0	02; Chi ² =	33.47,	df = 12	(P = 0.0	0008); P	² =64%			10	
Test for overall effect: Z =	4.94 (P	< 0.000	01)							-1 -0.5 U U.5 1 Eavours VCM Eavours no VCM
Test for subaroup differe	nces: Ch	ni ² = 0.0	4. df = 1	1 (P = 0)	85), I ^z =	0%				

Figure S6. Decisional Conflict by Implications/Presentation of Results

		VCM		n	o VCM		9	Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.1.1 Presentation of re	sults									
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003	
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	8.0%	-0.28 [-0.48, -0.09]	2007	
(uppermann 2014	12.9	14.1	357	13.8	15.6	353	9.7%	-0.06 [-0.21, 0.09]	2014	
∂arvelink 2014	41.6	9.5	66	44.1	12.3	66	4.4%	-0.23 [-0.57, 0.12]	2014	
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017	
lopkin 2019	14.59	15.04	122	23.13	20.34	136	6.5%	-0.47 [-0.72, -0.22]	2019	
Vitteman 2020 6c	36	26	440	42	27	422	10.2%	-0.23 [-0.36, -0.09]	2020	
Vitteman 2020 6b + 6c Subtotal (95% Cl)	36	27	413 1755	42	27	422 1775	10.1% 58.8 %	-0.22 [-0.36, -0.09] - 0.24 [-0.39, -0.09]	2020	
1.1.2 No presentation of	results									and the second sec
1.1.2 No presentation of	results									
rosh 2008	27.95	13.45	153	30	10.77	151	7.1%	-0.17 [-0.39, 0.06]	2008	
Epstein 2018	9.09	2.35	61	9.48	2.23	61	4.2%	-0.17 [-0.52, 0.19]	2018	1
Vitteman 2020 6b	39	27	395	42	27	422	10.0%	-0.11 [-0.25, 0.03]	2020	
Vitteman 2020 4b	35	28	350	42	27	422	9.9%	-0.25 [-0.40, -0.11]	2020	
Vitteman 2020 6a	35	27	363	42	27	422	9.9%	-0.26 [-0.40, -0.12]	2020	
Subtotal (95% CI)			1322			1478	41.2%	-0.20 [-0.27, -0.13]		•
Heterogeneity: Tau ² = 0.0	00; Chi =	= 2.96, c	lf = 4 (F	° = 0.56)	; I² = 09	6				
Fest for overall effect: Z =	: 5.28 (P	< 0.000	01)							
Fotal (95% CI)			3077			3253	100.0%	-0.22 [-0.31, -0.13]		•
Heterogeneity: Tau ² = 0.0	02; Chi ^z =	33.47,	df = 12	P = 0.0	0008); P	² = 64%	í.		35	
Fest for overall effect: Z =	4.94 (P	< 0.000	01)							Favours VCM Favours po VCM
Fest for subgroup differe	nces: Ch	ni ² = 0.2	4, df = 1	1 (P = 0.	62), I ^z =	0%				

Figure S7. Decisional Conflict by Stated Use of a Theory/Framework

		A CHI		n	O VCM			std. Mean Difference		Std. Mean Difference
study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.1.1 Stated theory										
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003	
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	8.0%	-0.28 [-0.48, -0.09]	2007	
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017	
Epstein 2018	9.09	2.35	61	9.48	2.23	61	4.2%	-0.17 [-0.52, 0.19]	2018	
Hopkin 2019	14.59	15.04	122	23.13	20.34	136	6.5%	-0.47 [-0.72, -0.22]	2019	
Subtotal (95% CI)			540			573	28.6%	-0.28 [-0.57, 0.02]		
Heterogeneity: Tau ² = 0.0)9; Chi ² =	22.86.	df = 4	P = 0.00	001); I ² :	= 83%				
Test for overall effect: Z =	1.85 (P	= 0.06)								
1.1.2 No stated theory or	r framew	vork								
Frosh 2008	27.95	13.45	153	30	10.77	151	7.1%	-0.17 [-0.39, 0.06]	2008	
Garvelink 2014	41.6	9.5	66	44.1	12.3	66	4.4%	-0.23 [-0.57, 0.12]	2014	
Kuppermann 2014	12.9	14.1	357	13.8	15.6	353	9.7%	-0.06 [-0.21, 0.09]	2014	
Witteman 2020 6b	39	27	395	42	27	422	10.0%	-0.11 [-0.25, 0.03]	2020	
Vitteman 2020 4b	35	28	350	42	27	422	9.9%	-0.25 [-0.40, -0.11]	2020	
Nitteman 2020 6c	36	26	440	42	27	422	10.2%	-0.23 [-0.36, -0.09]	2020	
/Vitteman 2020 6a	35	27	363	42	27	422	9.9%	-0.26 [-0.40, -0.12]	2020	
Witteman 2020 6b + 6c	36	27	413	42	27	422	10.1%	-0.221-0.36-0.091	2020	
Subtotal (95% CI)			2537	_		2680	71.4%	-0.19 [-0.24, -0.14]		•
Heterogeneity: Tau ² = 0.0	00: Chi ² =	6.54 c	f = 7 (F)	P = 0.48	: I ² = 09	6				1
Test for overall effect: Z =	6.85 (P	< 0.000	01)							
Fotal (95% CI)			3077			3253	100.0%	-0.22 [-0.31, -0.13]		•
Heterogeneity: Tau ² = 0 f	02: Chi ² =	33.47	df = 12	(P = 0)	0008) [,] I ^a	² = 64%			100	
Test for overall effect: 7 =	4 94 (P	< 0.000	01)			0170				-1 -0.5 0 0.5 1

Test for subgroup differences: $Chi^2 = 0.33$, df = 1 (P = 0.56), l² = 0%

Figure S8. Decisional Conflict by Real/Hypothetical

		VCM		n	IN VCM		5	Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl
1.1.1 Real decision										
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003	
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	8.0%	-0.28 [-0.48, -0.09]	2007	
Frosh 2008	27.95	13.45	153	30	10.77	151	7.1%	-0.17 [-0.39, 0.06]	2008	
Kuppermann 2014	12.9	14.1	357	13.8	15.6	353	9.7%	-0.06 [-0.21, 0.09]	2014	
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017	
Epstein 2018 Subtotal (95% Cl)	9.09	2.35	61 928	9.48	2.23	61 941	4.2% 39.0 %	-0.17 [-0.52, 0.19] -0.19 [-0.41, 0.03]	2018	-
Heterogeneity: Tau ² = 0.0	06: Chi ^z =	25.78.	df = 5	(P < 0.0	001): I ² :	= 81%		-		
Test for overall effect: Z =	1.66 (P	= 0.10)			,					
1.1.2 Hypothetical decis	ion									
Garvelink 2014	41.6	9.5	66	44.1	12.3	66	4.4%	-0.23 [-0.57, 0.12]	2014	
Hopkin 2019	14.59	15.04	122	23.13	20.34	136	6.5%	-0.47 [-0.72, -0.22]	2019	
/Vitteman 2020 6b	39	27	395	42	27	422	10.0%	-0.11 [-0.25, 0.03]	2020	
/Vitteman 2020 4b	35	28	350	42	27	422	9.9%	-0.25 [-0.40, -0.11]	2020	
/Vitteman 2020 6b + 6c	36	27	413	42	27	422	10.1%	-0.22 [-0.36, -0.09]	2020	
/Vitteman 2020 6c	36	26	440	42	27	422	10.2%	-0.23 [-0.36, -0.09]	2020	
Witteman 2020 6a	35	27	363	42	27	422	9.9%	-0.26 [-0.40, -0.12]	2020	
Subtotal (95% CI)			2149			2312	61.0%	-0.23 [-0.29, -0.17]		•
Heterogeneity: Tau² = 0.0 Test for overall effect: Z =	00; Chi² = : 7.07 (P	= 6.85, c < 0.000	#f = 6 (F 101)	P = 0.34)); I ^z = 12	!%				
Total (95% CI)			3077			3253	100.0%	-0.22 [-0.31, -0.13]		•
Heterogeneity: Tau ² = 0.0	02; Chi ² =	33.47.	df = 12	P = 0.1	0008); P	² = 64%			35	
Test for overall effect: Z =	4.94 (P	< 0.000	01)	<u>.</u>	20					-1 -0.5 U U.5 1
	120		23553							Favours yow Favours no yow

Test for subgroup differences: $Chi^2 = 0.13$, df = 1 (P = 0.72), $l^2 = 0\%$

Figure S9. Decisional Conflict by Risk of Bias

	VCM			no VCM				Std. Mean Difference		Std. Mean Difference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	Year	IV, Random, 95% Cl	
1.1.1 Low risk of bias or	some c	oncern	s								
Montgomery 2007	23.6	15.1	198	27.8	14.6	201	7.7%	-0.28 [-0.48, -0.09]	2007		
Frosh 2008	27.95	13.45	153	30	10.77	151	6.9%	-0.17 [-0.39, 0.06]	2008		
Garvelink 2014 2	41.6	9.5	66	44.1	12.3	65	4.4%	-0.23 [-0.57, 0.12]	2014		
Kuppermann 2014	12.9	14.1	357	13.8	15.6	353	9.1%	-0.06 [-0.21, 0.09]	2014		
Shirk 2017	2.5	0.9	59	2.2	0.9	63	4.2%	0.33 [-0.03, 0.69]	2017		
Epstein 2018	9.09	2.35	61	9.48	2.23	61	4.3%	-0.17 [-0.52, 0.19]	2018		
Hopkin 2019	14.59	15.04	122	23.13	20.34	136	6.4%	-0.47 [-0.72, -0.22]	2019		
/Vitteman 2020 6b + 6c	36	27	413	42	27	422	9.4%	-0.22 [-0.36, -0.09]	2020		
Witteman 2020 6c	36	26	440	42	27	422	9.5%	-0.23 [-0.36, -0.09]	2020		
Witteman 2020 4b	35	28	350	42	27	422	9.2%	-0.25 [-0.40, -0.11]	2020		
Witteman 2020 6a	35	27	363	42	27	422	9.3%	-0.26 [-0.40, -0.12]	2020		
Witteman 2020 6b	39	27	395	42	27	422	9.4%	-0.11 [-0.25, 0.03]	2020		
Subtotal (95% CI)			2977			3140	89.7%	-0.20 [-0.27, -0.12]		•	
Heterogeneity: Tau² = 0.(Test for overall effect: Z =	01; Chi² = : 5.26 (P	= 20.46, < 0.000	df = 11 01)	(P = 0.0	04); I² =	46%					
1.1.2 High risk of bias											
Montgomery 2003	27.6	12.1	100	38.9	18.3	112	5.7%	-0.72 [-1.00, -0.44]	2003		
Garvelink 2014 1	43.6	14.2	70	40.9	11.6	70	4.6%	0.21 [-0.13, 0.54]	2014		
Subtotal (95% CI)			170			182	10.3%	-0.26 [-1.17, 0.65]			
Heterogeneity: Tau ² = 0.4	40; Chi ² =	17.50,	df = 1	P < 0.00	001); I ^z :	= 94%					
Test for overall effect: Z =	0.56 (P	= 0.57)			18						
Total (95% CI)			3147			3322	100.0%	-0.20 [-0.29, -0.11]		•	
Heterogeneity: Tau ² = 0.0	02; Chi ^z =	39.50,	df = 13	(P = 0.0)	0002); P	² = 67%	,		35		
Test for overall effect: Z =	4.35 (P	< 0.000	1)	8						-1 -0.5 U U.5 1	
Test for subaroun differe	nces: Ch	ni [≠] = 0 0	2. df = 1	1 (P = 0)	89) I ^z =	0%				Favours vom Favours no vom	

Head-to-Head Evaluations of Values Clarification Methods

Feldman-Stewart et al. (2006) found no difference across all three groups (information only; values clarification method without a summary bar, i.e. rating scales; values clarification with a summary bar, i.e. multicriteria decision analysis) in terms of the attributes participants identified as important to their decisions nor in how difficult it was to make the decision. When trial participants were unblinded at the end of the study and shown all three options, all of them ranked the bars with the summary option (multicriteria decision analysis) as the most helpful.

Pignone et al. (2012) found that a discrete choice experiment produced somewhat different patterns of attribute importance compared to ranking and rating. Agreement between the most important attribute derived from the values clarification method and the most important attribute as reported by participants in the questionnaire was slightly higher in the ranking and rating arm than the discrete choice experiment arm. The authors found no difference between study arms in terms of values clarity, intent to be screened and unlabelled screening test preference.

Pignone et al. (2013) found that different values clarification methods produced differences in attribute importance and screening test preference. Participants who received the rating and ranking test were more likely to report the chance of dying from prostate cancer as the most important attribute compared to the balance sheet and discrete choice experiment groups. Those who received the balance sheet were more likely to prefer the unlabelled PSA-like test option compared to the two other groups. Participants who received the discrete choice experiment were somewhat less likely to select reduction of mortality as the most important attribute, and were least likely to select the PSA-like option on the unlabelled preference question. There was no difference across groups in intent to be screened (labelled PSA test option) nor on values clarity.

Brenner et al. (2014) found that different values clarification methods produced different results in terms of individuals' most important screening test attributes. Specifically, respondents who received the rating and ranking exercise, compared to a discrete choice experiment or a balance sheet (i.e., implicit values clarification method), were the most likely to choose risk reduction as the most important attribute. They found no differences in terms of test preferences, values clarity, nor intention to be screened.

Witteman et al. (2020) found that overall, methods using mathematical models (e.g., decision analysis, allocation of points) were more promising than other methods (e.g., pros and cons, rating scales) for encouraging values-congruent decisions. All methods encouraged lower decisional conflict when this was assessed.

Risk of Bias

Article	Random Sequence Generation (Selection Bias)	Allocation Concealme nt (Selection Bias)	Blinding of Participants and Personnel (Performanc e Bias)	Blinding of Outcome Assessment (Detection Bias)	Incomplete Outcome Data (Attrition Data)	Selective Reporting (Reporting Bias)	Other Bias
Abhyankar 2010	low	unclear	high	unclear	low	low	low
Au 2012	low	low	unclear	unclear	unclear	unclear	unclear
Bekker 2004	low	low	unclear	unclear	unclear	low	low
Brenner 2014	low	low	low	unclear	unclear	low	low
Clancy 1988	low	unclear	unclear	low	unclear	unclear	high
deAchaval 2012	low	low	low	low	low	low	low
Epstein 2018	low	unclear	unclear	high	unclear	low	unclear
Feldman-Stewart 2006	unclear	unclear	unclear	unclear	unclear	unclear	low
Feldman-Stewart 2012	low	low	unclear	low	low	unclear	low
Fraenken 2007	low	low	high	unclear	low	low	low
Frosch 2008	low	low	unclear	low	low	unclear	low
Garvelink 2014 (1)	low	low	low	low	unclear	low	high
Garvelink 2014 (2)	low	low	low	low	low	low	unclear
Hess 2015	low	low	unclear	unclear	unclear	low	unclear
Hopkin 2019	low	low	low	low	unclear	low	unclear
Hutyra 2019	low	unclear	low	low	low	low	unclear
Jayadevappa 2019	low	low	unclear	unclear	low	unclear	unclear
Kennedy 2002	low	low	high	unclear	low	unclear	unclear
Kuppermann 2014	low	low	low	low	low	low	unclear
Lehrman 1997	unclear	unclear	high	unclear	low	low	low
Matheis-Kraft 1997	unclear	unclear	unclear	unclear	low	unclear	unclear
Montgomery 2007	low	low	low	low	low	low	unclear
Montgomery 2003	low	low	high	low	low	unclear	low

Myers 2003	unclear	unclear	unclear	unclear	unclear	low	unclear
Myers 2005	unclear	unclear	unclear	unclear	low	low	unclear
O'Connor 1999	low	low	unclear	low	low	unclear	low
Paquin 2018	low	low	unclear	unclear	low	low	unclear
Peinado 2020	unclear	low	unclear	unclear	unclear	low	low
Pignone 2012	unclear	unclear	low	unclear	unclear	low	low
Pignone 2013	low	low	low	unclear	unclear	low	low
Sheridan 2010	low						
Shirk 2017	unclear	unclear	unclear	unclear	low	low	unclear
Witteman 2015	low	low	unclear	unclear	unclear	low	unclear
Witteman 2020	unclear	low	unclear	unclear	low	low	low

Online Appendix 4: PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	Title page
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3-5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	na
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Appendix 1
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7 - 8
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8-9
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis.	8-9

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	10-14
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	14
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	14-17
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	14-17
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	Appendix 3
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	14-17
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	17-18
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	18-19
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	19
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	20

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097